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ABSTRACT 
 
Hepatocellular carcinoma (HCC) is the most common type of human liver 
cancer and it is now the second leading cause of cancer death worldwide. In the 
United States, its incidence has tripled since 1980 and the death rates are 
increasing. RASSF1A (Ras association domain family 1 isoform A) is a tumor 
suppressor and frequently inactivated in HCC by promoter hypermethylation. 
However, the exact role and detailed mechanism of RASSF1A in the development 
of HCC has not been investigated. 
Autophagy is a catabolic pathway to degrade dysfunctional organelles and 
misfolded or aggregated proteins. Autophagy defects enhance oxidative stresses 
which trigger DNA damage and genome instability to promote tumorigenesis. The 
interaction of RASSF1A with microtubule-associated autophagy activator MAP1S 
triggered us to examine whether RASSF1A itself activates autophagy to suppress 
HCC through MAP1S. We show here first time that RASSF1A is essential to 
maintain autophagy activity and RASSF1A depletion causes decreased 
autophagy flux both in vitro and in vivo. RASSF1A-deletion-caused autophagy 
defects lead to an acceleration of diethylnitrosamine (DEN)-induced HCC and a 
31% reduction in mouse survivals.  
RASSF1A activates autophagy by enhancing both autophagy initiation and 
maturation. RASSF1A does not impact MAP1S-Bcl-2-p27 non-canonical 
autophagy initiation pathway but acts through the Hippo pathway-regulatory 
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protein Mst1 to promote autophagy initiation through PI3K-Akt-mTOR pathway, a 
major pathway suppressing autophagy initiation. Acetylated microtubules are 
required for the trafficking of autophagosomes to fuse with lysosomes. RASSF1A 
enhances microtubular acetylation and recruits LC3-II-associated 
autophagosomes onto RASSF1A-stabilized acetylated microtubules through 
MAP1S to promote autophagy maturation.  
In sum, in addition to identify RASSF1A as a novel regulator of autophagy, 
we show here first time that the epigenetic inactivation of RASSF1A actually 
promotes HCC and shortens survivals by suppressing autophagy initiation and 
maturation, which may provide a novel paradigm of the prevention and therapy of 
HCC.  
 iv 
 
DEDICATION 
 
I would like to dedicate this dissertation to my parents for their unconditional 
love, encouragement and support. 
 
 v 
 
ACKNOWLEDGEMENTS 
 
First of all, I would like to thank my mentor, Dr. Leyuan Liu, and my 
committee members, Dr. Fen Wang, Dr. Roderick H. Dashwood, Dr. Dekai Zhang, 
and Dr. Jason T Kimata, for their guidance and support throughout the course of 
this research. Dr. Liu offered me the precious opportunity to join his lab, and gave 
me the valuable guidance for my thesis study. More importantly, he always trained 
me think and work independently, which is essential for my future academic 
pursuit. Dr. Wang always gave me incisive questions to make me think deeper 
about my research. Dr. Dashwood always encouraged me to participate in public 
presentations to improve communication skills, and his questions broadened my 
perspective in cancer research area. Dr. Zhang always offered me precious 
suggestions to my presentation and research. Dr. Kimata always gave me 
insightful suggestions for my project and helped me improve my writing skills.  
I would also like to thank all the faculties and staffs at Texas A&M University 
Institute of Bioscience and Technology. They create a relaxed and friendly 
atmosphere which makes my time here a great experience. Special gratitude goes 
to graduate student program for their support. Thanks to student program 
coordinator Ms. Cynthia Lewis, who is always patient to answer all of my questions 
and warmly help me solve all the administrative issues. My gratitude also goes to 
all the members in Dr. Liu’s lab for their kindness. I am very thankful to Dr. Fei 
Yue in the lab, who always share experimental materials, good idea and new 
 vi 
 
techniques with me. Thanks to Dr. Stefan Siwko for his precious advice for my 
study and life. I am also grateful for my friends in IBT, Yanqing Huang, Yixiang 
Xu, Junchen Liu, Lei An, Lian He, Ji Jing, Li Zeng, Yifan Zhang, Yi Liang et al. 
Their company, friendship and kindness make my life in Houston full of fun and 
happiness.   
Last but not least, thanks to my boyfriend Yuan Dai and my family for their 
love, encouragement and support.  
  
 vii 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
Contributors 
This work was supervised by a dissertation committee consisting of 
Professors Leyuan Liu (advisor) and Fen Wang of the Center for Translational 
Cancer Research in Texas A&M Health Science Center IBT and Professor 
Roderick H. Dashwood of the Center for Epigenetics & Disease Prevention in 
Texas A&M Health Science Center IBT and Professor Dekai Zhang of the Center 
for Infectious and Inflammatory Diseases in Texas A&M Health Science Center 
IBT and Professor Jason T Kimata of the Department of Molecular Virology and 
Microbiology in Baylor College of Medicine. 
All work conducted for the dissertation was completed by the student, 
under the advisement of Dr. Leyuan Liu. 
 
Funding Sources 
This work was funded by National Institutes of Health under Grant Number 
R01CA142862 to Leyuan Liu.  
 
 viii 
 
NOMENCLATURE 
 
AMPK AMP-activated protein kinase 
ATGs Autophagy-related genes 
ATM Ataxia telangiectasia mutated 
BAF Bafilomycin A1 
Bax Bcl-2-associated X protein 
Bcl-xL B-cell lymphoma-extra large 
Bcl-2 B-cell lymphoma 2 
BNIP3L/NIX Bcl-2 interacting protein 3 like 
BSA Bovine Serum Albumin 
C19ORF5 Chromosome 19 open reading frame 5 
CQ Chloroquine 
DAB 3, 3’-Diaminobenzidine 
DEN Diethylnitrosamine 
DHE Dihydroethidium hydrochloride 
DMEM Dulbecco’s Modified Eagle Medium 
DSB DNA double-strand breaks 
EBSS Earle’s Balanced Salt Solution 
ER Endoplasmic reticulum 
FBS Fetal Bovine Serum 
FL Full length 
 ix 
 
GAP GTPase-activating protein 
HBD HDAC4-binding domain 
HBV Hepatitis B 
HBSS Hanks’ Balanced Salt Solution 
HC Heavy chain 
HCC Hepatocellular carcinoma 
HCV Hepatitis C 
HDAC4 Histone deacetylase 4 
HDAC6 Histone deacetylase 6 
HEK Human embryonic kidney 
HRP Horseradish peroxidase 
HSC Hepatic stellate cells 
H&E Hematoxylin and Eosin 
ITS-G Insulin-Transferrin-Selenium 
LC Light chain 
LC3 Microtubule-associated protein 1 light chain 3 
LKB1 Liver kinase B1 
LRPPRC Leucine-rich PPR motif-containing protein 
MAP1S Microtubule-Associated Protein 1 Small form 
MDM2 Mouse double minute 2 
MEF Mouse embryonic fibroblast 
MOAP-1 Modulator of apoptosis 1 
 x 
 
Mst Mammalian sterile 20-like kinase 
mTOR Mammalian target of rapamycin 
PBS Phosphate-buffered saline 
PE Phosphatidylethanolamine 
PI3K Phosphatidylinositol 3-phosphate kinase 
PI3P Phosphatidylinositol-3-P 
PMSF Phenylmethanesulfonyl fluoride 
PVDF Polyvinylidene difluoride 
p27 Cyclin-dependent kinase inhibitor 1B 
RASSF1A Ras association domain family 1 isoform A 
Rheb Ras homolog enriched in brain 
ROS Reactive oxygen species 
Sav1 Salvador homolog 1 
SC Short chain 
SDS-PAGE SDS-polyacrylamide gels 
SQSTM1 Sequestosome 1 
TBST Tris-buffered Saline with Tween-20B/CS 
 xi 
 
TABLE OF CONTENTS 
 
 Page 
ABSTRACT ......................................................................................................      ii 
DEDICATION ...................................................................................................     iv 
ACKNOWLEDGEMENTS ................................................................................     v 
CONTRIBUTORS AND FUNDING SOURCES ................................................    vii 
NOMENCLATURE ...........................................................................................   viii 
TABLE OF CONTENTS ...................................................................................   xi 
LIST OF FIGURES ...........................................................................................   xiii 
LIST OF TABLES .............................................................................................   xv 
CHAPTER I INTRODUCTION ..........................................................................     1 
CHAPTER II DEPLETION OF RASSF1A RESULTS IN  
DECREASED AUTOPHAGY FLUX .................................................................   13 
                    Introduction ..................................................................................   13 
                    Materials and Methods .................................................................   15 
                    Results .........................................................................................   22 
                    Discussion ....................................................................................   27 
CHAPTER III DELETION OF RASSF1A GENE IN MICE ACCELERATES 
DEN-INDUCED HEPATOCARCINOGENESIS ................................................   30 
                    Introduction ..................................................................................   30 
                    Materials and Methods .................................................................   36 
                    Results .........................................................................................   40 
                    Discussion ....................................................................................   48 
CHAPTER IV RASSF1A PROMOTES AUTOPHAGY MATURATION BY 
RECRUITING AUTOPHAGOSOMES ONTO RASSF1A-STABILIZED 
ACETYLATED MICROTUBULES THROUGH MAP1S ....................................   50 
 xii 
 
          Introduction ..................................................................................   50 
                    Materials and Methods .................................................................   52 
                    Results .........................................................................................   59 
                    Discussion ....................................................................................   72 
CHAPTER V RASSF1A PROMOTES AUTOPHAGY INITIATION BY 
SUPPRESSING PI3K-AKT-MTOR PATHWAY THROUGH HIPPO  
PATHWAY REGULATORY PROTEIN MST1 ..................................................   75  
                    Introduction ..................................................................................   75 
                    Materials and Methods .................................................................   78 
                    Results .........................................................................................   82 
                    Discussion ....................................................................................   92 
CHAPTER VI CONCLUSIONS ........................................................................   97 
REFERENCES ................................................................................................ 102 
 
 
 xiii 
 
LIST OF FIGURES 
 Page 
Figure 1     Overview of the dynamic process of autophagy .............................     2 
Figure 2     Map of RASSF1 gene and structure of RASSF1A protein ..............     8 
Figure 3     Knockdown of RASSF1A in HeLa cells causes reduced 
                  autophagy ......................................................................................   23 
Figure 4     Deletion of RASSF1A gene in mice causes reduced                       
                  autophagy flux in MEFs ..................................................................   24 
Figure 5     Deletion of RASSF1A gene causes reduced autophagy flux 
                  in mouse livers ...............................................................................   26 
Figure 6     Deletion of RASSF1A causes no abnormality in mouse livers         
                  under normal conditions .................................................................   40 
Figure 7     Deletion of RASSF1A gene in mice accelerates DEN-induced   
                  hepatocarcinogenesis ....................................................................   42 
Figure 8     RASSF1A knockout mice have a shorter lifespan   
                  than wild-type mice with DEN treatment .........................................   43 
Figure 9     Deletion of RASSF1A enhances oxidative stresses 
                  in mouse livers ...............................................................................   45 
Figure 10   Deletion of RASSF1A promotes DNA damage in mouse livers ....   47 
 
Figure 11   RASSF1A deletion causes reduced levels of acetylated 
                  α-tubulin in mouse livers .................................................................   60    
Figure 12   RASSF1A enhances the acetylation of α-tubulin and                                   
                  associates with acetylated α-tubulin ...............................................   61 
Figure 13   RASSF1A interacts with HDAC6 ....................................................   62 
Figure 14   RASSF1A interacts with LC3-II .......................................................   64 
Figure 15   RASSF1A interacts with MAP1S via the overlapping domain  
                  between heavy chain (HC) and short chain (SC) of MAP1S ..........   66 
 
 xiv 
 
Figure 16   RASSF1A interacts with MAP1S via the RA domain ......................   67 
Figure 17   The interaction of RASSF1A with LC3-II requires MAP1S .............   69    
Figure 18   RASSF1A recruits autophagosomes onto RASSF1A-stabilized 
                  acetylated microtubules through MAP1S ........................................   71 
Figure 19   RASSF1A has no impact on MAP1S-mediated autophagy  
                  initiation pathway in HeLa cells .......................................................   83 
Figure 20   RASSF1A has no impact on MAP1S-mediated autophagy  
                  initiation pathway in mouse livers ...................................................   84 
Figure 21   RASSF1A suppression causes the activation of  
                  PI3K-Akt-mTOR pathway in HeLa cells ..........................................   86  
Figure 22   RASSF1A deletion causes the activation of PI3K-Akt-mTOR 
                  pathway in mice ..............................................................................   87 
Figure 23   RASSF1A suppresses PI3K-Akt-mTOR pathway to promote     
                  autophagy initiation through Hippo pathway regulatory protein  
                  Mst1 ...............................................................................................   89 
Figure 24   RASSF1A deletion has no impact on the downstream  
                  effectors of Hippo pathway .............................................................   91  
Figure 25   A diagram showing the potential mechanism by which RASSF1A 
                  regulates autophagy and suppresses hepatocarcinogenesis ........  99 
 xv 
 
LIST OF TABLES 
 Page 
 
Table 1      Primers used for mouse genotyping PCR .......................................   16 
Table 2     Primers used for real-time PCR analyses of mouse RASSF1A 
                 mRNA levels ...................................................................................   20 
Table 3      Primers used for plasmid construction ............................................   54 
 
 
 
 1 
 
CHAPTER I  
INTRODUCTION  
 
Cancer, the second leading cause of death worldwide, causes over 8 
million deaths worldwide in every recent year (1). Hepatocellular carcinoma 
(HCC), a primary malignancy of the liver, is the second most common lethal 
cancer worldwide and its incidence has tripled in recent decades in the United 
States (2,3). There are many risk factors for liver cancer, mainly including chronic 
Hepatitis B (HBV) or Hepatitis C (HCV) infection, alcoholic liver disease and non-
alcoholic fatty liver disease. Other risk factors, such as hereditary 
hemochromatosis, alpha-antitrypsin deficiency, autoimmune hepatitis, some 
porphyrias, and Wilson’s disease, also contribute to the formation and progression 
of liver cancer. Most of these risk factors cause liver cirrhosis, and the long-term 
chronic injuries in liver finally promote the formation of HCC. Clinical statistic data 
showed that 80-90% patients with HCC also develop liver cirrhosis. Currently, it 
is very difficult to diagnose HCC at very early stage. Therefore, only a small 
portion of patients with early-stage HCC receive curative treatments including 
surgical resection or liver transplantation. Currently, there are no very effective 
treatments for most patients with late-stage HCC and the 5-year survival rate has 
remained below 12%. Considering the poor prognosis and high mortality, it is 
urgent to understand the exact molecular mechanisms underlying HCC 
development for developing novel therapeutic strategies. 
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Autophagy was first observed in the 1960s and it is a major catabolic 
pathway to degrade misfolded or aggregated proteins, dysfunctional organelles 
and other macromolecules (4,5). Autophagy is a dynamic process that begins with 
the formation of isolation membranes. The membranes then engulf substrates to 
form the compartment known as autophagosomes. Autophagosomes migrate 
along acetylated microtubules to finally fuse with lysosomes to generate 
autolysosomes in which substrates are degraded by lysosomal enzymes (Figure 
1). Therefore, the autophagic process can be generally divided into two main 
steps: autophagy initiation and autophagy maturation.  
 
 
 
 
 
 
Figure 1. Overview of the dynamic process of autophagy (6). Modified from 
Hansen TE, Johansen T: Following autophagy step by step. BMC Biology 
2011, 9:39. 
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Although autophagy has been studied mainly in mammalian cells after 
being first reported in 1957 in mammalian cells (7), the groundbreaking 
experiments in the identification of its molecular regulators were conducted in 
yeast in the 1990s (8). One of the key regulators of autophagy is the mammalian 
target of rapamycin (mTOR) which negatively regulates autophagy initiation (9). 
In the presence of insulin and growth factors, the well-characterized class I 
phosphatidylinositol 3-phosphate kinase (PI3K)-protein kinase B (Akt)-mTOR 
signaling pathway is activated to inhibit autophagy induction. mTOR can also 
inhibit autophagy induction through the liver kinase B1 (LKB1)-AMP-activated 
protein kinase (AMPK)-mTOR pathway in response to nutrients and metabolites. 
Downstream of the mTOR, a number of autophagy-related genes (ATGs) 
encoding proteins that are essential for the execution of autophagy have been 
identified so far. According to the functions in distinct stages of autophagy 
process, ATG proteins can be classified into three main groups. The first one is 
the ATG1 complex (ATG1, ATG13, ATG17) that is commonly considered as the 
initiator of the autophagic cascade (8,10). Under nutrient-rich conditions, mTOR 
is activated and then directly phosphorylates and inactivates ATG13 to prevent 
the formation of ATG1 initiator complex. Meanwhile, ATG1 is also 
hyperphosphorylated by activated mTOR, resulting in a reduction in ATG1 kinase 
activity and the subsequent inhibition of autophagy initiation. Upon starvation, 
ATG1 and ATG13 are rapidly dephosphorylated and form a complex, which leads 
to the recruitment of other ATG proteins to promote autophagy induction. After 
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autophagy is initiated, class III phosphoatidylinositol-3-kinase (PI3K) complex 
(ATG6, ATG14, and VPS34) is responsible for the phagophore nucleation. As a 
core component of class III PI3K complex, ATG6 binds to VPS34 (class III PI3K) 
and modulates its lipid kinase activity. This lipid kinase complex then 
phosphorylates phosphoinositides to produce phosphatidylinositol-3-P (PI3P), 
which leads to the recruitment of important autophagy proteins involved in 
phagophore nucleation (11). Two ubiquitin-like conjugation systems are required 
for the expansion of phagophore and the completion of autophagosome 
formation. One is the ATG12 conjugation system (ATG5, ATG12, and ATG16). 
ATG12, an ubiquitin-like protein, is first activated by an ubiquitin-activating 
enzyme (E1)-like protein ATG7 and then transferred to ATG5 by ATG10, an 
ubiquitin carrier protein (E2)-like protein. ATG12 covalently conjugates with ATG5 
and then recruits ATG16 to form the ATG12-ATG5-ATG16 complex which 
specifically targets to the membranes of early autophagosomes and functions as 
the E3-like enzyme for another ubiquitin-like conjugation system: LC3 
(microtubule-associated protein 1 light chain 3, the mammalian homolog of ATG8) 
lipidation system (ATG3, ATG7, and LC3). Once autophagy is initiated, the 22-KD 
full-length LC3 precursor, an ubiquitin-like protein, is first cleaved by cysteine 
protease ATG4 to expose the conserved C-terminal Gly120 to produce the 
cytosolic LC3-I. Subsequently, LC3-I is activated by ATG7 and then transferred to 
ATG3, another ubiquitin carrier protein (E2)-like protein. ATG3-LC3-I conjugates 
target to the isolation membrane initiation sites and then the C-terminal glycine 
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covalently conjugates with the membrane lipid molecule 
phosphatidylethanolamine (PE) to generate PE-conjugated LC3 (called LC3-II) 
with the assistance of ATG12-ATG5-ATG16 complex. LC3-II is localized in both 
outer and inner membranes of phagophores and is considered to be important for 
the membrane extension and the eventual membrane closure (12). After mature 
autophagosomes form, the ATG12 complex disassociates, whereas LC3-II still 
associates with autophagosomal membrane and is eventually degraded in 
lysosomes. 
LC3-II is now widely used as a key marker to monitor autophagy process 
(12,13). After lipidation, LC3-II tightly associates with autophagosomal membrane 
and plays an important role in the process of selective autophagy. Autophagic 
cargo receptors such as p62/SQSTM1 (sequestosome 1), NBR1 (neighbor of 
Brca1 gene), NDP52 (nuclear dot protein 52 kDa) and BNIP3L/NIX (Bcl-2 
Interacting Protein 3 Like) can directly bind to the autophagosome-associated 
LC3-II through a LC3-interacting region (LIR) (14) so that the target cargo are 
enveloped by the phagophore membrane to form autophagosomes. 
Autophagosome-associated LC3-II also serves as a linker to bridge mature cargo-
containing autophagosomes with microtubules for trafficking. Finally, 
autophagosomes fuse with lysosomes and LC3-II is degraded in lysosomes 
together with substrates. Therefore, the conversion of LC3-1 to LC3-II indicates 
autophagosomal biogenesis and the degradation of LC3-II indicates 
autophagosomal degradation. If the degradation of LC3-II is blocked by lysosomal 
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inhibitor, such as bafilomycin A1 (BAF), chloroquine (CQ) or ammonium chloride 
(NH4Cl), the amount of accumulated LC3-II can be used to quantify the 
autophagic activity. Western blot is one of the most popular assay to detect levels 
of LC3-I and LC3-II. Although the PE-conjugated LC3 (LC3-II) has a larger mass, 
it shows faster electrophoretic mobility in SDS-PAGE gels, probably due to its 
increased hydrophobicity. Therefore, LC3-I (approximately 16-18 KD) and LC3-II 
(approximately 14-16 KD) can be separated well on SDS-PAGE gels (13). A 
fluorescent protein tagged LC3, such as GFP-LC3 or RFP-LC3, is also widely 
used to monitor autophagic activity by fluorescent microscopy. Under nutrient-rich 
conditions, GFP-LC3 or RFP-LC3 diffuse in the cytoplasm. Upon autophagy is 
activated, GFP-LC3 or RFP-LC3 translocate to autophagosomal membranes and 
present as fluorescent punctate foci. Therefore, as a good fluorescent marker for 
autophagosomes, GFP-LC3 or RFP-LC3 punctate foci can be used for 
quantification of autophagic activity. Transgenic mice systemically expressing 
GFP-LC3 has been generated to monitor the autophagic activity in vivo (15).   
Increasing evidences have showed that autophagy is a tumor suppressor 
pathway. The link between autophagy and tumorigenesis was first established in 
1999, when the ATG gene Beclin1 (the homolog of ATG6 in yeast) was discovered 
to express at a decreased level in breast, ovarian and prostate cancers (16,17). 
Monoallelic deletion of Becclin1 in mice results in a significant reduction in 
autophagy flux and the development of spontaneous tumors (18,19). 
Subsequently, studies showed that mice lacking an autophagy-regulatory protein, 
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such as ATG4, ATG5, ATG7, Bif1 or MAP1S also exhibit a reduction in autophagy 
activity and an increase in tumorigenesis (20-22). Studies in these vivo models 
highlight the critical role of autophagy in tumor suppression. It has been 
demonstrated that autophagy defects promote tumorigenesis by destabilizing 
genome (23-25). Under normal conditions, autophagy occurs at a very low level 
to maintain cellular homeostasis. Under unfavorable conditions, autophagy can 
be rapidly activated to play a protective role by removing the damaged 
components, such like the damaged organelles and protein aggregates. 
Conversely, autophagy defects lead to the accumulation of damaging 
components which create a tumor-promoting environment by enhancing the 
production of reactive oxygen species (ROS). In addition to further damage 
cellular components, the enhanced ROS can trigger DNA double-strand breaks 
(DSB) and genome instability to promote tumorigenesis. Mice with either allelic 
loss of beclin1 or deletion of ATG5 or ATG7 exhibit increased DNA damage and 
genome instability. 
Ras association domain family 1 isoform A (RASSF1A) is a tumor 
suppressor. Allelic loss of the 3p21.3 region of the human genome occurs 
frequently in lung cancer (26,27). In 2000, the gene located at this region was first 
cloned and named RASSF1, because the protein contains a putative Ras 
association domain (28). RASSF1 gene spans about 11,000 bp and contains eight 
exons, two CpG islands and two different promoters (Figure 2A). RASSF1 family 
has eight different isoforms (RASSF1A-RASSF1H) due to the alternative splicing 
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and the usage of the two different promoters. Among the eight isoforms, only 
RASSF1A has been subjected to the extensive studies. It is a 340-residue protein, 
containing four characterized domains: C1 domain, phorbol ester/diacylglycerol 
binding domain; ATM domain, ataxia-telangiectasia mutated domain; RA domain, 
Ras-association (RalGDS/AF-6) domain; SARAH (Salvador-RASSF-Hippo) 
domain, Mst and Sav1 binding domain (Figure 2B). 
 
 
 
 
 
 
 
RASSF1A is showed to have multiple different biological functions related 
to tumor suppression. RASSF1A localizes to and stabilizes microtubules. It is 
reported that RASSF1A inhibits cell mitosis by localizing to centrosomes, spindle 
microtubules, spindle poles, midzone and midbody (29,30). The ability to stabilize 
Figure 2. Map of RASSF1 gene and structure of RASSF1A protein. (A) A 
diagram showing the RASSF1 gene locus. (B) A diagram showing the domain 
structure of RASSF1A protein. 
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microtubules also enables RASSF1A to inhibit cell migration (31,32). It is also 
reported that RASSF1A induces cell cycle arrest by directly interacting with cell 
division cycle protein 20 (Cdc20) to block its ability to activate the anaphase-
promoting complex (APC) (33). In addition to inhibit cell mitotic progression, 
RASSF1A is also reported to promote cell apoptosis through modulator of 
apoptosis 1 (MOAP-1) and mammalian sterile 20-like kinase (Mst)/ protein 
salvador homolog 1 (Sav1) (34-36). RASSF1A directly interacts with MOAP-1 
through its C1 domain, which relieves the inhibitory intramolecular interaction of 
MOAP-1 and promotes the association of MOAP-1 with Bcl-2-associated X 
protein (Bax). The increased association leads to the conformational change of 
Bax, mitochondrial membrane insertion, cytochrome c release and eventually 
apoptosis. RASSF1A is also reported to promote apoptosis by enhancing the 
transcription of some proapoptotic genes. RASSF1A directly interacts with 
Mst/Sav1 through its SARAH domain to activate Mst-mediated proapoptotic 
signaling pathway, which causes the translocation of transcriptional factor Yap in 
to nucleus. Yap associates with p73 (a homologue of tumor suppressor p53) to 
enhance the transcription of the proapoptotic genes. Studies showed that 
RASSF1A also promotes DNA damage response (37,38). Upon DNA damage, 
DNA damage checkpoint protein ataxia telangiectasia mutated (ATM) 
phosphorylates RASSF1A on Ser131 at its ATM domain, which leads to the Mst-
mediated apoptosis. It also showed that RASSF1A directly interacts with mouse 
double minute 2 (MDM2, also known as E3 ubiquitin-protein ligase) through its C1 
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domain, which sequesters MDM2 away from p53 and inhibits MDM2-mediated 
ubiquitination and degradation of p53. The activated p53 induces cell-cycle arrest 
and apoptosis to maintain genome integrity.  
RASSF1A is frequently inactivated by hypermethylation of CpG island in 
the promoter region in numerous human cancers, such as bladder, lung, kidney, 
breast and ovarian cancers (39-41). In human HCC, RASSF1A promoter 
methylation occurs at the highest frequency. Meta-analyses showed that 
RASSF1A gene has an aberrant promoter methylation in about 90% of human 
HCC tissues (42,43). However, the exact role of RASSF1A in the development of 
HCC has not been investigated. In order to improve the limited therapy and poor 
prognosis of HCC patients, it is imperative to understand the exact role and 
detailed mechanism of RASSF1A in this deadly disease. 
Microtubule-associated protein 1 small form (MAP1S), originally named as 
C19ORF5 (chromosome 19 open reading frame 5), is a microtubule-associated 
autophagy activator. It was first identified in 2002 as an interactive partner of 
leucine-rich PPR motif-containing protein (LRPPRC). Similar to its homologue of 
neuronal-specific MAP1A and MAP1B, the full length MAP1S(FL) is post-
translationally modified into multiple isoforms, including heavy chain (HC), short 
chain (SC) and light chain (LC) (44). Autophagy marker microtubule-associated 
protein 1 light chain 3 (LC3) was first discovered as an interactive partner of 
MAP1A and MAP1B (45,46). The interaction with MAP1A/B facilitates the 
microtubule association of LC3. In addition to MAP1A/B, we previously reported 
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that MAP1S-FL, HC, SC, but not LC, also interact with LC3, enabling MAP1S to 
bridge autophagosomes with microtubules to affect autophagosomal biogenesis 
and degradation (47). Moreover, we also found that MAP1S is able to promote 
autophagy initiation through the p27-mediated non-canonical autophagy pathway 
(47,48). MAP1S activates autophagy to suppress HCC. MAP1S-deleted mice 
have accelerated formation of liver tumor foci and develop more malignant 
hepatocellular carcinomas with diethylnitrosamine (DEN) treatment (25). MAP1S-
deleted mice also have a significant 5.6-month reduction in lifespans compared 
with wild-type mice (49). In addition, our previous studies showed that MAP1S can 
be used as a novel marker for the prognosis of patients with prostate 
adenocarcinomas (PCA) and clear cell renal cell carcinoma (ccRCC) (50,51). 
Patients with low levels of MAP1S usually exhibit worse clinical features and have 
a shorter survival time than those with high levels of MAP1S. 
MAP1S was identified as a major interactive protein of RASSF1A in the 
yeast two-hybrid analysis in a human liver and brain cDNA library (52,53). The 
interaction of RASSF1A with autophagy activator MAP1S triggered us to examine 
whether RASSF1A activates autophagy through MAP1S. Considering the 
frequent inactivation of RASSF1A gene in human liver cancer and the critical role 
of autophagy in tumor suppression, we were triggered to hypothesize that 
RASSF1A depletion may promote hepatocarcinogenesis by suppressing 
autophagy. Indeed, in this study we show that RASSF1A enhances the acetylation 
of microtubules, interacts with MAP1S and recruits LC3-II-associated 
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autophagosomes onto acetylated microtubules through MAP1S to promote 
autophagy maturation; and RASSF1A interacts with Hippo pathway-regulatory 
protein Mst1 and enhances Mst1 stability to inhibit PI3K-Akt-mTOR pathway to 
promote autophagy initiation. RASSF1A deletion in mice leads to reduced 
autophagy flux which promotes oxidative stresses, DNA damage and DEN-
induced HCC and shortens mouse survivals.        
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CHAPTER II  
DEPLETION OF RASSF1A RESULTS IN DECREASED AUTOPHAGY FLUX   
 
Introduction  
RASSF1A belongs to RASSF1 (Ras association domain family 1) family. 
RASSF1 gene locates in the 3p21.3 region of the human genome. The frequent 
allelic loss of this region in human lung cancers promotes people to try to identify 
the protein encoded by this region. The gene was successfully cloned and 
characterized to a human RAS effector homologue (RASSF1) in 2000 (28). 
Among the eight identified different isoforms of RASSF1 (RASSF1A-RSSF1H), 
only RASSF1A is subjected to extensive studies.  
RASSF1A is found to be frequently inactivated by promoter 
hypermethylation in numerous human cancers. To elucidate the mechanism by 
which RASSF1A exerts its tumor suppressive activities, Dallol et al. performed a 
yeast two-hybrid analysis in 2004 to identify the direct binding partners of 
RASSF1A in a human brain cDNA library (52). Consistent with our previous 
reports that MAP1S interacts with RASSF1A in a yeast two-hybrid analysis in a 
human liver cDNA library (53), they found that microtubule-associated proteins, 
including MAP1B and MAP1S, are the major interactive partners of RASSF1A. 
Subsequent studies showed that RASSF1A can colocalize with MAP1S on 
microtubules and promote microtubule stabilization (52,54). It is also reported that 
MAP1S recruits RASSF1A to spindle poles to inhibit mitotic progression (30). 
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MAP1A/B, the homologues of MAP1S, was reported to facilitate the association 
of LC3 with microtubules by interacting with LC3 (12,46). In addition, MAP1B was 
found to be involved in the regulation of autophagosomal trafficking in neurons 
(55). In addition to the microtubule dynamics regulation, we previously reported 
that MAP1S also plays a significant role in autophagy regulation. MAP1S-deleted 
mice exhibit decreased autophagy flux (47). MAP1S recruits LC3 to microtubules 
to promote autophagosomal biogenesis and degradation. The interaction of 
RASSF1A with autophagy activator MAP1S triggered us to reason that RASSF1A 
may also play a role in autophagy regulation. Indeed, here we show that 
RASSF1A depletion leads to a reduction in autophagy flux both in vitro and in 
vivo.   
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Materials and Method 
Animals 
All animal protocols were approved by the Institutional Animal Care and 
Use Committee (IACUC), Institute of Biosciences and Technology, Texas A&M 
Health Science Center. All animals received humane care according to the criteria 
outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by 
the National Academy of Sciences and published by the National Institutes of 
Health (NIH publication 86-23 revised 1985). C57BL/6 RASSF1A-/- mice were 
gifts from Dr. Pfeifer, the Center for Epigenetics, Van Andel Research Institute. 
C57BL/6 wild-type and RASSF1A-/- mice were bred and genotyped as described 
(56). Primers used for mouse genotyping PCR analyses are listed in Table 1. 
GFP-LC3 transgenic mice were gifts from Dr. Noboru Mizushima, the Department 
of Physiology and Cell Biology, Tokyo Medical and Dental University Graduate 
School and Faculty of Medicine. Chloroquine (CQ) (Sigma, #C6628) is a 
lysosomal inhibitor and was used to block autophagosomal degradation by raising 
the lysosomal pH. Mice were intraperitoneally injected with 50mg/kg body weight 
of CQ dissolved in saline per day for four days. Liver tissues were then harvested 
immediately after the animals were euthanized by CO2 asphyxiation. 
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Table 1. Primers used for mouse genotyping PCR. 
 
 
 
Cell Culture 
HeLa, HeLa cells stably expressing ERFP-LC3 (HeLa-RFP-LC3), and 
mouse embryonic fibroblast (MEF) cells were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) (GenDEPOT, #CM001) containing 10% Fetal Bovine 
Serum (FBS) (GenDEPOT, #F0900) and antibiotics (Thermo Scientific, 
#SV30010). Primary mouse hepatocytes were cultured in William’s E culture 
media (Sigma, #W4125) with 10% FBS, antibiotics, Insulin-Transferrin-Selenium 
(ITS-G) (Invitrogen, #51300-044) and 100 nM dexamethasone (Sigma, D4902). 
Phosphate-buffered saline (PBS) of pH 7.4 and 0.25% trypsin (GenDEPOT, 
#CA014) were used for subculture. All cells were cultured in a tissue culture 
incubator at 37°C with 5% CO2. 
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siRNA and Cell Transfection 
The negative control siRNA (Invitrogen, #AM4635) was purchased from 
Invitrogen. The siRNAs specific to human RASSF1A (Santa Cruz, #sc-44070) 
was from Santa Cruz Biotechnology. HeLa cells or HeLa cells stably expressing 
ERFP-LC3 (HeLa-RFP-LC3) were transfected with random or RASSF1A-specific 
siRNAs by using Oligofectamine (Invitrogen, #12252-011) according to the 
manufacturer’s recommended instruction. The total proteins were harvested at 48 
hours after transfection. 
 
Western Blotting 
Cells or mouse tissues were lysed in lysis buffer (50 mM HEPES, pH 7.5, 
150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% Triton X-100, 10% Glycerol, 1 
mM NaF) with 1 mM phenylmethanesulfonyl fluoride (PMSF) (Sigma, #P7626) 
and protease inhibitor cocktail (Sigma, #P8849) on ice. The total protein extracts 
were harvested by centrifugation. The protein concentration was determined by 
using BCA protein assay kit (Thermo Scientific, #23225). The lysates mixed with 
sodium dodecyl sulfate (SDS) loading buffer were then boiled for 10 minutes. 
Lysates containing the equal amounts of protein were separated by SDS-
polyacrylamide gels (SDS-PAGE) and transferred onto polyvinylidene difluoride 
(PVDF) membranes (GE Health, #10600023). The membranes were blocked with 
5% (w/v) non-fat milk dissolved in Tris-buffered Saline with Tween-20 (TBST) for 
1 hour at room temperature and then incubated with primary antibodies overnight 
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at 4°C. The primary antibodies and the dilutions are: anti-RASSF1A (Abcam, 
#ab23950), 1:1000; anti-LC3 (Novus Biologicals, #NB100-2331), 1:1000; anti-β-
Actin, (Santa Cruz, #47778), 1:2000; and anti-GAPDH, (Santa Cruz, #25778), 
1:2000. After being washed with TBST buffer to remove nonspecific antibodies, 
the membranes were then incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (Bio-Rad, #172-1011, #170-6515, dilution 
1:10000) for 1 hours at room temperature. After being washed with TBST buffer 
to remove the unbound antibodies, the specifically bound antibodies were 
detected by using ECL Prime Western Blotting Detection Reagents (GE Health, 
#RPN2232). The membranes were imaged by exposing to X-ray films (Pheonix, 
#F-BX57). Finally, the relative intensity of a band to the internal control was 
measured by using the ImageJ software (NIH). 
 
Fluorescent Confocal Microscopy 
HeLa-RFP-LC3 cells or primary hepatocytes derived from GFP-LC3 
transgenic mice were treated with 10 nM lysosomal inhibitor balifomycin A1 (BAF) 
(Sigma, #11707) for 6 hours. Cells were then fixed with 4% (w/v) 
paraformaldehyde (Sigma, #P6148) in PBS for 30 minutes at room temperature. 
Images were captured with a Zeiss LSM 510 Meta Confocal Microscope. The 
number of RFP-LC3 or GFP-LC3 punctate foci on each image was calculated by 
using ImageJ software. 
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Establishment of Mouse Embryonic Fibroblasts (MEFs) 
Mouse embryonic fibroblasts (MEFs) were prepared from wild-type 
(RASSF1A+/+) and RASSF1A knockout mice (RASSF1A-/-) as described (47). 
Briefly, embryos collected at E12.5-14.5 were minced in Dulbecco’s modified 
Eagle’s medium (DMEM), incubated with 0.25% trypsin at 37 °C for 10 min and 
then filtered through 70 µm cell strainer (Corning, # 352350). The separated cells 
were then harvested and cultured in DMEM containing 10% Fetal Bovine Serum 
(FBS) (GenDEPOT, #F0900) and antibiotics (Thermo Scientific, #SV30010). 
 
Real-time Reverse Transcription (RT)-PCR 
Total RNA was isolated from wild-type or RASSF1A-/- MEFs with Trizol 
reagent (Invitrogen, #15596-026) according to the manufacturer’s instructions. 
Reverse transcription was performed using the Invitrogen SuperScript III reverse 
transcriptase with random primers. Real-time PCR reactions were performed 
using SYBR Premix ExTaq (TaKaRa, #RR820A). Primers used for real-time PCR 
analyses of mouse RASSF1A mRNA levels are listed in the Table 2. The 
abundance of mRNA was calculated by using the comparative threshold (CT) 
cycle method. Relative quantification of mRNA was achieved by normalization to 
the amount of β-actin. 
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Table 2. Primers used for real-time PCR analyses of mouse RASSF1A 
mRNA levels 
 
 
 
Isolation of Primary Mouse Hepatocytes 
Mouse primary hepatocytes were isolated from 12-week-old male wild-type 
(RASSF1A+/+) and RASSF1A knockout mice (RASSF1A-/-) by the two-steps liver 
perfusion method as previously described (57). Briefly, mice were anesthetized 
and the portal vein was catheterized after cutting open the abdomen. The liver 
was then first perfused in situ with Earle’s Balanced Salt Solution (EBSS) 
(Invitrogen, #14115-063) containing 0.5 mM EGTA (Sigma, #E4378) for 8-10 min 
with the inferior vena cava cut and then perfused for 5 min with Hanks’ Balanced 
Salt Solution (HBSS) (Invitrogen, #14170-112) supplemented with 0.3mg/ml type 
IV collagenase (Roche, #11088874103). After perfusion, the liver was extirpated, 
transferred into plates filled with DMEM, removed of gallbladder and gently 
squeezed to help hepatocytes detach. Then cell suspension was filtered through 
sterile 70 μm cell strainers, washed by centrifugation at 600 rpm for 2 min at RT, 
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resuspended in Percoll (GE Health, #17-0891-02)/10XHBSS (Invitrogen, #14185-
052) (9:1) mixture and centrifuged at 600 rpm for 15 min at RT. Cell viability was 
examined by Trypan Blue staining. After centrifugation, pellet was washed and 
seeded at dish. 
 
Statistical Analysis 
Statistically significant effects were examined using Student’s t-test. A P 
value of less than 0.05 was considered significant and significance were set to *, 
p ≤ 0.05; **, P ≤ 0.01; and ***, P ≤ 0.001. Error bars represent standard deviation. 
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Results 
Knockdown of RASSF1A in HeLa Cells Leads to Decreased Autophagy Flux 
Due to the hypermethylation of CpG island in promoter region, RASSF1A 
is epigenetically inactivated in numerous cancer cell lines. However, HeLa cells 
retain the expression of RASSF1A. Therefore, to examine whether RASSF1A 
regulates autophagy, RASSF1A-specific siRNA was first utilized to suppress the 
expression of RASSF1A in HeLa cells and levels of the key autophagy marker 
LC3-II was measured to represent autophagy flux. With lysosomal inhibitor 
bafilomycin A1 (BAF) treatment, RASSF1A-suppressed HeLa cells had less 
accumulated LC3-II than the control cells (Figure 3A, B), indicating that RASSF1A 
knockdown caused a reduction in autophagy flux. To confirm this result, we then 
suppressed the expression of RASSF1A in HeLa cells stably expressing RFP-
LC3 to observe the amounts of RFP-LC3 punctate foci representing 
autophagosomes. Expectedly, RASSF1A-suppressed cells exhibited a significant 
reduction in the number of RFP-LC3 punctate foci (Figure 3C, D) and the intensity 
of RFP-LC3 band and endogenous LC3-II band (Figure 3E, F) in the presence of 
BAF. Therefore, knockdown of RASSF1A in HeLa cells results in a reduction in 
autophagy flux. 
 
 
 
 
 23 
 
 
 
Figure 3. Knockdown of RASSF1A in HeLa cells causes reduced 
autophagy flux. (A, B) Immunoblot analysis (A) and quantification (B) of LC3-
II levels in HeLa cells treated with random (Mock) or RASSF1A-specific siRNAs 
(RA) in the absence (Ctrl) or presence of lysosomal inhibitor BAF (10 µM 
overnight before harvest). (C, D) Representative fluorescent images (C) and 
quantification (D) of RFP-LC3 punctate foci in HeLa cells stably expressing 
RFP-LC3 treated with random (Mock) or RASSF1A-specific siRNAs in the 
absence (Ctrl) or presence of BAF. Scale bar, 10µM. (E, F) Immunoblot 
analysis (E) and quantification (F) of levels of RFP-LC3 and endogenous LC3-
II in similar cells as shown in (C). *, P ≤ 0.05; **, P ≤ 0.01. 
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Deletion of RASSF1A Gene Leads to Decreased Autophagy Flux in Mouse 
Embryonic Fibroblasts (MEFs) 
To examine whether RASSF1A depletion also results in decreased 
autophagy flux in mice, we first isolated MEFs from wild-type and RASSF1A-/-  
mice and measured levels of autophagy flux. The genotyping results (Figure 4A) 
and the quantitative real-time PCR analyses (Figure 4B) confirmed the deletion of 
RASSF1A gene in RASSF1A-/- mice. As expected, RASSF1A deletion led to a 
reduced accumulation of LC3-II in the presence of BAF (Figure 4C, D). Therefore, 
RASSF1A deletion causes reduced autophagy flux in MEFs. 
 
 
 
 
 
Figure 4. Deletion of RASSF1A gene in mice causes reduced autophagy 
flux in MEFs. (A) PCR analysis of DNA samples from MEFs to genotype wild-
type and RASSF1A-/- MEFs. (B) Quantitative real-time PCR analysis of levels 
of RASSF1A mRNA in MEFs derived from wild-type and RASSF1A-/- mice. (C, 
D) Immunoblot analysis (C) and quantification (D) of LC3-II levels in wild-type 
and RASSF1A-/- MEFs in the absence (Ctrl) or presence of BAF. *, P ≤ 0.05. 
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Deletion of RASSF1A Gene Leads to Decreased Autophagy Flux in Mouse Livers 
We then examined the impact of RASSF1A on autophagy flux in mouse 
livers which are highly depend on autophagy to maintain their functions (58). In 
the presence of BAF, RASSF1A deletion resulted in a reduction of LC3-II levels 
in mouse primary hepatocytes, indicating a decreased autophagy flux (Figure 5A, 
B). Such reduction in autophagy flux was confirmed by a significant reduction in 
the number of GFP-LC3 punctate foci in BAF-treated hepatocytes isolated from 
GFP-LC3 transgenic RASSF1A-/- mice (Figure 5C, D). To further confirm this 
result, levels of autophagy flux were examined in three pairs of male littermates 
of wild-type and RASSF1A-/- mice intraperitoneally injected with lysosomal 
inhibitor chloroquine (CQ) (50mg/kg per day) for four days. CQ accumulates in 
lysosomes and raises lysosomal pH to inhibit lysosomal enzymes that require an 
acidic pH. Immunoblot analysis showed that in the presence of CQ, liver tissues 
from RASSF1A-/- mice had decreased levels of LC3-II compare to the wild-type 
mice (Figure 5E, F). Therefore, deletion of RASSF1A gene causes reduced 
autophagy flux in mouse livers. 
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Figure 5. Deletion of RASSF1A gene causes reduced autophagy flux in 
mouse livers. (A, B) Immunoblot analysis (A) and quantification (B) of LC3-II 
levels in wild-type and RASSF1A-/- hepatocytes in the absence (Ctrl) or 
presence of BAF. (C, D) Representative fluorescent images (C) and 
quantification (D) of GFP‐LC3 punctate foci in hepatocytes isolated from GFP-
LC3 transgenic wild-type and RASSF1A-/- mice. Scale bar, 10µM. (E, F) 
Immunoblot analysis (E) and quantification (F) of LC3-II levels in liver tissues 
from wild-type and RASSF1A-/- mice injected with saline (Ctrl) or lysosomal 
inhibitor CQ. **, P ≤ 0.01.  
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Discussion 
Autophagy is a highly conserved self-digestion process. As a house 
keeper, autophagy maintains cellular homeostasis by degrading aged or 
dysfunctional organelles and protein aggregates. Autophagy also has a key role 
in promoting cellular survival during starvation by providing nutrients, and 
protecting cells from stresses-induced damage by degrading damaged cellular 
components.  
Among all the autophagy-related proteins, LC3 is most widely used to 
monitor and quantify autophagy activity (13). LC3 was first identified in 1994 as a 
co-purified protein with MAP1A/B in rat brain and proposed to regulate the 
microtubule binding activity of MAP1A/B (46). In 2000, LC3 was identified as the 
first mammalian protein associated with autophagosomal membrane (12). Upon 
autophagy is initiated, the full length LC3 precursor is first truncated into cytosolic 
LC3-I which then conjugates with autophagosomal membrane component 
phosphatidylethanolamine (PE) to be anchored to autophagosomal membrane. 
Finally, PE-associated LC3, also known as LC3-II, is degraded in lysosomes along 
with substrates. Therefore, the amount of LC3-II represents the number of 
autophagosomes. Due to the generated LC3-II is constantly degraded by 
lysosomes, the increased levels of LC3-II may indicate the enhanced conversion 
of LC3-I to LC3-II or the impaired autophagosomal degradation by lysosomes. 
Therefore, to correctly monitor autophagy activity, we usually measure the total 
amounts of LC3-II after the autophagosomal degradation is blocked by a 
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lysosomal inhibitor, such like bafilomycin A1 (BAF), chloroquine (CQ) or 
ammonium chloride (NH4Cl). In this chapter, by using western blots and GFP or 
RFP-LC3 punctate foci forming assay, we show first time that in the presence of 
lysosomal inhibitor, RASSF1A depletion causes reductions in levels of LC3-II and 
number of GFP or RPF-LC3 punctate foci both in vitro and in vivo, indicating that 
RASSF1A depletion leads to a reduction in autophagy activity.  
Microscopic anatomy study shows that liver is formed by two major types 
of cells, including parenchymal hepatocytes (hereafter hepatocytes) and non-
parenchymal cells. In this study, we mainly examined the impact of RASSF1A on 
autophagy flux in hepatocytes. Hepatocytes that constitute 60% of the total 
number of liver cells perform the majority of hepatic functions, such as 
carbohydrate metabolism, bile production, protein synthesis and storage, 
excretion of exogenous and endogenous substances. Hepatocytes have more 
lysosomes and lysosomal enzymes such as cathepsin than other cell types, 
indicating that hepatocytes have a higher autophagy activity (59). Studies showed 
that hepatocytes are highly dependent on autophagy to execute their metabolic 
functions. Alteration in hepatic autophagy significantly impacts the hepatic 
physiology and causes liver diseases (58).  
The other 40% of liver cells are non-parenchymal cells, such like hepatic 
stellate cells (HSC), sinusoidal endothelial cells, phagocytic Kupffer cells and 
lymphocytes. Whether RASSF1A deletion also causes a reduced autophagy flux 
in these non-parenchymal liver cells or not is not investigated in this study. 
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Although the role of autophagy in these non-parenchymal cells is poorly 
understood, it is reported that autophagy plays a significant role in HSC activation 
(60). Activated HSC are the key cellular source of extracellular matrix synthesis in 
the process of liver fibrosis (61). Therefore, determining the role of RASSF1A-
regulated autophagy in HSC activation may provide a novel paradigm in the 
prevention of liver fibrosis. 
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CHAPTER III  
DELETION OF RASSF1A GENE IN MICE ACCELERATES DEN-INDUCED 
HEPATOCARCINOGENESIS   
 
Introduction  
Hepatocellular carcinoma (HCC) is the second leading cause of cancer 
mortality worldwide. In 2016, more than 35,000 people were diagnosed with liver 
cancer in the United States and more than 25,000 people died (3). The death 
rates caused by HCC are increasing. Although HBV vaccination and antiviral 
treatment against HBV or HCV infection can reduce the risk of HCC, very effective 
treatments for HCC are not available currently (2). For the patients with very early 
stage HCC, the surgical resection is one of the most appropriate treatment. 
However, the already existed chronic injuries in livers continue to promote the 
formation of new HCC. Therefore, there is as high as 70% recurrence risk of HCC 
in 5 years after surgery. Another most appropriate treatment for very early stage 
HCC patients is liver transplantation. The 5-year survival rate can reach up to as 
high as 75% after transplantation. However, currently, it is very difficult to 
diagnose the very early stage HCC which is defined as a single, asymptomatic 
lesion with less than 2 cm in diameter and no vascular or distant metastases. Only 
13% of patients with HCC in the United States are diagnosed early enough to 
receive surgical resection or liver transplantation, but the prognosis of HCC 
patients is very poor and the 5-year survival rate is less than 12% (62). Therefore, 
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there is an urgent need to define the exact molecular mechanisms underlying 
HCC development for developing novel therapeutic strategies. 
Autophagy, a cellular self-degradation process, plays an important role in 
maintaining diverse functions of livers. First, liver is particular dependent on 
autophagy to maintain the balance of energy and nutrients (58). In response to 
starvation, autophagy in livers is significantly activated to supply hepatocytes with 
the necessary nutrients for survival by degrading intracellular materials. Studies 
showed that mice starved for 48 hours can lose up to 40% of total liver proteins 
per hour, while mice in normal conditions just lose 1.5% of total liver proteins 
(63,64). Hepatocytes have a large number of mitochondria which are particular 
rich in proteins and lipids. In addition to protein degradation during starvation, 
selective mitochondria degradation by autophagy (also known as mitophagy) also 
occurs, which accounts for approximately 85% of autophagy events in the cultured 
hepatocytes (65,66). Hepatocytes from ATG5, ATG7 or Beclin1-deficient mice are 
characterized by the accumulation of protein aggregates as well as damaged 
mitochondria (21,23). In addition, during starvation, the blood glucose levels of 
liver-specific ATG7 deletion mice declined within a larger range than wild-type 
mice, suggesting that autophagy also plays an important role in maintaining 
hepatic glucose levels (67). It is also found that liver mediates the degradation of 
hepatocellular triglycerides (TGs) and lipid droplets (LDs), which is known as 
lipophagy (68). Lipophagy provides hepatocytes with free fatty acids (FFAs) to 
promote cellular ATG production, which balances cellular metabolism and energy 
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generation. Autophagy was also found to be implicated in the immune response 
of livers. Liver, the largest immune organ in the body, faces the continuous 
challenge of orally-ingested antigens and intestinal bacteria released products 
such as lipopolysaccharide (LPS). Liver is also the major target of a number of 
liver viruses, such like HBV, HCV and dengue virus (DENV). Studies showed that 
autophagy can sense microbial infection and then stimulate the toll-like receptor 
(TLR) signaling. The activated TLR in turn promotes autophagy induction (69,70). 
Studies also showed that autophagy functions in the degradation of microbes 
(known as xenophagy) and the process of antigen for MHC presentation (71-76). 
Taken together, in liver, autophagy has an essential role in the turnover of protein 
aggregates, dysfunctional or damaged organelles, and other macromolecules to 
maintain its basic functions. 
Autophagy defects promote tumorigenesis, including liver tumors. The 
evidence first came from a study in 1999 which shows that the induced autophagy 
activity by the essential autophagy protein Beclin1 is associated with the 
decreased tumorigenesis ability of human MCF7 breast carcinoma cells (16). 
Subsequently, the inverse relationship between autophagy and tumorigenesis 
was well established by the examination of mice with loss of autophagy-related 
genes. Mice with allelic loss of Beclin1 are partially defective for autophagy and 
develop spontaneous hepatocellular carcinomas as well as other cancers, such 
as lung cancer and lymphomas (18,19). Mice with deficiency in an autophagy-
related gene such as ATG7, Beclin1-interactive protein Bif1 (also known as 
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Endophilin B1), or ATG5, also exhibit a reduction in autophagy activity and an 
increase in spontaneous tumor incidence at advanced age (21,22). In addition, 
mice with ATG4C (one of the four mammalian ATG4 homologues) deficiency are 
more prone to develop fibrosarcomas with chemical carcinogens treatment (20). 
We previously found that mice with the novel autophagy activator MAP1S 
deficiency also showed an increased susceptibility to develop DEN-induced 
hepatocarcinomas (25). Natural component spermidine prevents DEN-induced 
HCC and prolongs mouse lifespans by activating MAP1S-mediated autophagy 
(57). Taken together, autophagy plays a critical role in suppressing tumorigenesis. 
Defective autophagy enhances oxidative stresses which trigger DNA 
double strand break (DSB) and genome instability to promote tumorigenesis 
(5,23,25,77). Autophagy defects lead to the excessive accumulation of damaged 
organelles and protein aggregates that enhance the production of oxidative 
stress. The aged or damaged mitochondria are the major source of reactive 
oxygen species (ROS) (78,79). Oxidative protein folding is another source of 
oxidative stress (80). Studies showed that the accumulation of damaged or 
misfolded proteins in cytosol increase the burden on endoplasmic reticulum (ER) 
protein folding machinery (24). The generated ROS in turn further damages the 
surrounding cellular components to enhance ROS production. Enhanced ROS 
causes telomere attrition and DNA double-strand breaks (DSB) and 
simultaneously subverts mitotic checkpoints (81-84). Therefore, instead of 
oxidative stress-triggered cell death, some cells with DNA damage can survive 
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from the weakened mitotic checkpoint. The broken chromosomal fragment tends 
to randomly fuse with another chromosomal fragment, which potentially results in 
the formation of a new chromosome with two centromeres (85). During mitotic 
metaphase, chromosomal bridge forms. After telophase, chromosomal bridge 
breaks and generates new broken ends. If cells with DSB escape from the 
weakened mitotic checkpoint, they will produce aneuploidy daughter cells. 
Survived aneuploidy cells potentially initiate a cascade of autocatalytic karyotypic 
evolution through the continuous chromosomal breakage-fusion-bridge cycles 
(86). Eventually the genome is destabilized to promote tumorigenesis. Liver is 
particular dependent on autophagy to maintain its diverse functions (58). The 
critical role of autophagy in suppressing hepatocarcinogenesis has been well 
demonstrated by the studies in vivo models. Mice with loss of an autophagy-
related gene such as Beclin1, ATG5, ATG7 or MAP1S, exhibit a reduced 
autophagy activity and an increased incidence of liver tumors (21,23). Studies 
also showed that autophagy-deficient tumor cells have accumulated swelling 
mitochondria, ubiquitinated protein aggregates, oxidative stress, DNA damage 
and genome instability. 
RASSF1A, a tumor suppressor, is epigenetically silenced by promoter 
hypomethylation in over 90% of human HCC tissues. However, the exact role and 
detailed mechanism of RASSF1A in the development of HCC has not been 
investigated. In chapter II, we have demonstrated that RASSF1A deletion causes 
reduced autophagy flux in mouse livers. Considering the critical role of autophagy 
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in suppressing HCC formation, we reasoned that RASSF1A deletion may 
accelerate the formation of HCC by suppressing autophagy flux. Indeed, here we 
show that RASSF1A-deletion-caused autophagy defects in mouse livers enhance 
oxidative stresses and genome instability to promote DEN-induced HCC and 
shorten survival times of mice suffering from HCC.   
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Materials and Methods 
Animals 
All animal protocols were approved by the Institutional Animal Care and 
Use Committee (IACUC), Institute of Biosciences and Technology, Texas A&M 
Health Science Center. All animals received humane care according to the criteria 
outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by 
the National Academy of Sciences and published by the National Institutes of 
Health (NIH publication 86-23 revised 1985). Diethylnitrosamine (DEN) (Sigma, 
#0756) was used as a carcinogenic reagent to induce liver tumors as previously 
described (25,87). 15-day-old wild-type and RASSF1A-/- male littermates were 
intraperitoneally injected with a single dose of DEN of 10 µg/g body weight 
dissolved in saline. Mice were euthanized by CO2 asphyxiation at 6, 7, 9, 12 
months after DEN injection. Immediately after euthanasia, mice were weighted 
and livers were excised, weighed, and photographed. Ratio of liver weight to body 
weight (LW/BW) at each time point were recorded. Grossly visible surface tumors 
of each liver were scored. Liver tissues were frozen or fixed for further analyses. 
For the survival analysis, mice with DEN injection at 15 days after birth were 
observed to record their survival times when they were found dead or when they 
were found to be moribund. 
 
Cell Culture 
HeLa cells were cultured in DMEM medium containing 10% FBS and 
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antibiotics. PBS of pH 7.4 and 0.25% trypsin were used for subculture. Cells were 
cultured in a tissue culture incubator at 37°C with 5% CO2. 
 
siRNA and Cell Transfection 
HeLa cells were transfected with random or RASSF1A-specific siRNAs by 
using Oligofectamine according to the manufacturer’s recommended instruction. 
The total proteins were harvested at 48 hours after transfection. 
 
Western Blotting 
Cells or mouse tissues were lysed in lysis buffer with 1 mM PMSF and 
protease inhibitor cocktail on ice. The protein concentration was determined by 
using BCA protein assay kit. The lysates mixed with SDS loading buffer were then 
boiled for 10 minutes. Lysates containing the equal amounts of protein were 
separated by SDS-PAGE gels and transferred onto PVDF membranes. The 
membranes were blocked with 5% (w/v) non-fat milk in TBST for 1 hour at room 
temperature and then incubated with primary antibodies overnight at 4°C.  The 
primary antibodies and the dilutions are: anti-RASSF1A (Abcam, #ab23950), 
1:1000; anti- γ-H2AX (Cell Signaling, #9718S), 1:1000; and anti-β-Actin, (Santa 
Cruz, #47778), 1:2000. After being washed with the TBST buffer to remove 
nonspecific antibodies, the membranes were then incubated with HRP-
conjugated secondary antibodies for 1 hours at room temperature. After being 
washed with the TBST buffer to remove the unbound antibodies, the specifically 
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bound antibodies were detected by using ECL Prime Western Blotting Detection 
Reagents. Then, the membranes were imaged by exposing to X-ray films. Finally, 
the relative intensity of a band to the internal control was measured by using the 
ImageJ software (NIH). 
 
Dihydroethidium (DHE) Staining 
A part of frozen samples was cryosectioned and used for measurement of 
oxidative stress. The cryosections were stained with 2 mM dihydroethidium 
hydrochloride (DHE) (Invitrogen, #D-1168) for 30 minutes at 37 °C as previously 
described (49). DHE is able to permeate into cells and be oxidized by cytosolic 
ROS. The oxidized DHE then intercalates into genomic DNA to labels nuclei with 
red fluorescent signals which represent levels of oxidative stress in cells. The 
fluorescent signals were monitored by fluorescent microscopy and the intensities 
of signals were quantified by ImageJ software. 
 
Histology 
Liver tissues were fixed with 4% paraformaldehyde-PBS solution for 24 
hours. The fixed liver tissues were then serially dehydrated, embedded in paraffin 
and sectioned. For general histology, liver tissue sections were re-hydrated and 
stained with hematoxylin (Fisher Scientific, #SH26) and Eosin (H&E) (Sigma, 
#HT110116). The occupied area of liver tumor foci was quantified by ImageJ 
software. For immunohistochemistry staining, liver sections were first re-hydrated 
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and boiled in citrate buffer (10 mM sodium citrate, 0.05% Tween-20), pH 8.0 for 
20 minutes to retrieve antigen. Sections were then stained with γ-H2AX (Cell 
Signaling, #9718, dilution 1:500) using HRP/ 3, 3’-Diaminobenzidine (DAB) 
detection IHC kit (Abcam, #64261) according to the manufacturer’s instruction. 
The sections were finally counterstained with hematoxylin to label nuclei. 
 
Statistical Analysis 
Statistically significant effects were examined using Student’s t-test. A P 
value of less than 0.05 was considered significant and significance were set to *, 
p ≤ 0.05; **, P ≤ 0.01; and ***, P ≤ 0.001. Error bars represent standard deviation. 
The overall survival and median survival times of mice were analyzed by the 
Kaplan-Meier method. The significance of difference between wild-type and 
RASSF1A-/- mice was estimated by log-rank test. 
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Results 
Deletion of RASSF1A Gene Causes No Abnormality in Mouse Livers under 
Normal Conditions 
RASSF1A gene is frequently inactivated by promoter hypermethylation in 
human HCC tissues. To investigate the function of RASSF1A in HCC, we first 
maintained 3 pairs of male littermates of wild-type and RASSF1A-/- mice under 
normal conditions for months to observe HCC formation. We were unbale to 
detect any tumor foci on the liver surfaces up to 12 months (Figure 6A). As 
displayed by hematoxylin and eosin (H&E) staining, no abnormality associated 
with the onset of neoplasia was detected in liver tissues from wild-type and 
RASSF1A-/- mice (Figure 6B). 
 
 
 
 
 
Figure 6. Deletion of RASSF1A causes no abnormality in mouse livers 
under normal conditions. (A) The morphology of livers from 12-month-old 
wild-type and RASSF1A-/- mice. (B) A comparative H&E staining of livers as 
shown in (A). Scale bar, 20µM. 
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Deletion of RASSF1A Gene in Mice Accelerates DEN-induced 
Hepatocarcinogenesis 
Although deletion of RASSF1A gene may not be sufficient to induce liver 
cancer under normal conditions, we reasoned that RASSF1A deletion may 
accelerate liver cancer formation under certain types of stresses. DEN is widely 
used as a carcinogenic reagent to induce liver cancer in mice (87). We started to 
intraperitoneally inject 15 days-old male littermates of wild-type and RASSF1A-/- 
mice with a single dose of DEN (10 µg/g body weight) to induce HCC. We started 
to observe small liver surface tumors in RASSF1A-/- mice at 6 months and wild-
type mice at 7 months after DEN treatment (Figure 7A). At this stage, although 
the body weights and liver weights were not significantly different (Figure 7B, C), 
RASSF1A-/- mice developed more liver surface tumors (Figure 7A, E) and larger 
tumor foci (Figure 7F, G). When mice became older, the large tumor foci occupied 
almost the entire liver surfaces of DEN-treated 12 months-old RASSF1A-/- mice, 
and RASSF1A-/- mice exhibited higher liver weights (Figure 7C) and liver/body 
weight ratios (Figure 7D) than wild-type mice. Histologically, at 12 months after 
DEN treatment, wild-type mice had about 40% area with normal liver structures, 
10% with encircled tumor foci and 50% area with typical HCC trabecular structure, 
while RASSF1A-/- mice had only 10% area with encircled tumor foci, 65% typical 
HCC trabecular structure and 25% highly distorted liver structures (Figure 7H). 
Therefore, RASSF1A deletion promotes DEN-induced hepatocarcinogenesis. 
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Figure 7. Deletion of RASSF1A gene in mice accelerates DEN-induced 
hepatocarcinogenesis. (A) Representative images of liver tissues from DEN-
treated wild-type and RASSF1A-/- mice at different ages. Black arrows indicate 
liver surface tumors. (B-E) Plots of body weights (B), liver weights (C), ratios 
of body weight to liver weight (D), and the number of surface tumors (E) to ages 
of DEN-treated wild-type and RASSF1A-/- mice as shown in (A). (F) A 
comparative H&E staining of liver tissues from DEN-treated 6-month-old mice 
as shown in (A). Scale bar, 20µM. (G) Relative size of tumor foci as shown in 
(F). (H) A comparative H&E staining of liver tissues from DEN-treated 12-
month-old mice as shown in (A). Scale bar, 20µM. *, P ≤ 0.05; **, P ≤ 0.01.  
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Deletion of RASSF1A Gene Causes Reduced Lifespan of DEN-treated Mice 
Due to the accelerated hepatocarcinogenesis, RASSF1A-/- mice had a 
significant 174 days reduction in lifespan (or 31% reduction in median survival 
times, hazard ratio of 12.85) compared with wild-type mice in the presence of DEN 
(Figure 8). 
 
 
 
 
 
 
 
 
 
Figure 8. RASSF1A knockout mice have a shorter lifespan than wild-type 
mice with DEN treatment. The Kaplan-Meier survival curves showing the 
survival times of DEN-treated wild-type and RASSF1A-/- mice. n, number of 
mice; MSD, median survival days. The significance of difference between two 
groups was estimated by log-rank test, and P value for each plot was the 
probability larger than the chi-square value.  
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Deletion of RASSF1A Gene Enhances Oxidative Stress in Mouse Livers 
Autophagy defects enhance oxidative stresses which further trigger DNA 
double-strand breaks (DSB) and genome instability to promote tumorigenesis 
(5,23,25,77). In chapter II, we have shown that RASSF1A deletion leads to a 
reduced autophagy flux in mouse livers. To examine whether RASSF1A-deletion-
caused autophagy defects contribute to the accelerated hepatocarcinogenesis, 
we first measured levels of oxidative stresses in mouse livers by performing 
dihydroethidium (DHE) fluorescence assay. Cytosolic ROS oxidize DHE after 
DHE permeates into cells. The oxidized DHE then intercalates into genomic DNA 
and labels nuclei with red fluorescent signals. We intraperitoneally injected 3 pairs 
of male littermates of wild-type and RASSF1A-/- mice at 15-day-old with a single 
dose of either vehicle or DEN (10 µg/g body weight). Two days later, liver tissues 
were collected, immediately cryosectioned and stained with 2 mM DHE for 30 min 
at 37°C. There was no significant difference in levels of oxidative stress in liver 
tissues between wild-type and RASSF1A-/- mice under normal conditions. 
However, at two days after DEN treatment, RASSF1A-/- mice exhibited high levels 
of oxidative stress as indicated by the elevated intensity of red fluorescent signals 
(Figure 9A, B). Therefore, RASSF1A deletion enhances oxidative stress in mouse 
livers. 
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Figure 9. Deletion of RASSF1A enhances oxidative stresses in mouse 
livers. (A) Comparative analyses of levels of oxidative stress revealed by 
dihydroethidine hydrochloride (DHE) staining among liver tissues from wild-
type and RASSF1A-/- mice treated with vehicle (Ctrl) or DEN for two days. 
Scale bar, 50µM. (B) Quantification of the relative levels of oxidative stress as 
shown in (A) by ImageJ software. **, P ≤ 0.01; ***, P ≤ 0.001; ns, nonsignificant, 
P > 0.05. 
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Deletion of RASSF1A Gene Promotes DNA Damage in Mouse Livers 
Oxidative stress resulted from autophagy defects trigger DNA double 
strand break (DSB) and genome instability to promote tumorigenesis. We then 
examined whether the elevated oxidative stresses in RASSF1A-/- mice lead to 
increased DNA damage. Knockdown of RASSF1A in HeLa cells caused a 
significant increase in γ-H2AX levels (Figure 10A, B), the marker of DNA double 
strand breakage (88). Consistently, RASSF1A deletion also caused elevated 
levels of γ-H2AX in mouse liver tissues collected at 6 months after DEN treatment 
compared to wild-type mice (Figure 10C, D). The immunohistochemistry staining 
further showed that with DEN treatment, liver tissues from RASSF1A-/- mice had 
a dramatically increased number of cells positively stained with γ-H2AX compared 
with wild-type mice (Figure 10E, F). Therefore, RASSF1A deletion promotes DNA 
damage in mouse livers. 
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Figure 10. Deletion of RASSF1A promotes DNA damage in mouse 
livers. (A, B) Immunoblot analysis (A) and quantification (B) of γ-H2AX 
levels in HeLa cells treated with random (Mock) or RASSF1A-specific 
siRNAs. (C, D) Immunoblot analysis (C) and quantification (D) of γ-H2AX 
levels in liver tissues from DEN-treated 6-month-old wild-type and 
RASSF1A-/- mice as shown in Figure 7A. (E) Representative 
immunostaining of γ-H2AX in liver tissue sections of DEN-treated wild-type 
and RASSF1A-/- mice at different ages as shown in Figure 7A. Red arrows 
indicate γ-H2AX positive cells. Scale bar, 20 µm. (F) Quantification of the 
percentage of γ-H2AX positive cells in total cells of liver tissue sections as 
shown in (E). **, P ≤ 0.01; ***, P ≤ 0.001. 
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Discussion 
Autophagy-lysosome pathway plays a critical role in maintaining cellular 
homeostasis by degrading misfolded or aggregated proteins, dysfunctional 
organelles and other macromolecules. Autophagy defects enhance oxidative 
stresses (5,77). Reactive oxygen species (ROS) destabilize genome by causing 
telomere attrition and DNA double strand breakage (DSB) and simultaneously 
subverting mitotic checkpoints (81-84). If cell with a destabilized genome escapes 
from the weak mitotic checkpoints, it potentially initiates a cascade of autocatalytic 
karyotypic evolution through continuous cycles of chromosomal breakage-fusion-
bridge and eventually destabilizes genome to promote tumorigenesis (77,86).  
In addition to promote cancer initiation, autophagy defects also promote 
cancer development. Although it is believed that the established tumor cells utilize 
autophagy to survive metabolic stresses, such like low nutrient and hypoxia, 
studies showed that autophagy defects in established tumor cells can promote 
tumor progression (23,25). Autophagy defects lead to different types of cell death 
including apoptosis, necrosis, and pyroptosis (89,90). Oxidative stress or 
lysosomal rupture resulted from autophagy defects activate NLRP3 
inflammasomes, which leads to the activation of caspase-1 to induce a type of cell 
death referred to as pyroptosis (91-93). Pyroptosis is an inflammatory form of cell 
death and characterized by the release of proinflammatory cytokines that can fuel 
pro-inflammatory cascades to cause the death of other cells in the environment 
(94-96). Furthermore, in established tumor cells, autophagy defects further 
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promote DNA damage due to the inability of tumor cells to remove oxidative 
stress. The subverted cell cycle checkpoints and apoptosis resistance in tumor 
cells may allow further manifestation of genome damage. A destabilized genome 
leads to increased mutation rate in the remaining viable tumor cells, which 
facilitates tumor progression. Therefore, autophagy defects promote both initiation 
and development of cancer. 
Although RASSF1A-/- mice with decreased autophagy activity did not 
develop spontaneous HCC under normal conditions, they exhibited an 
accelerated initiation and development of HCC with chemical carcinogen DEN 
treatment, which is consist with the suppressive role of autophagy in 
tumorigenesis. In addition, reduction in autophagy activity led to elevated levels 
of oxidative stress and DNA damage both of which accelerate DEN-induced 
initiation and progression of HCC. Autophagy prolongs mouse lifespans (49,57). 
DEN-treated RASSF1A-/- mice lived much shortened lifespans than the DEN-
treated wild-type mice possibly also due to the reduced autophagy activity.  
Taken together, we show here first time that epigenetic inactivation of 
tumor suppressor RASSF1A actually promotes HCC by suppressing autophagy 
flux, which may provide a novel paradigm of the prevention and therapy of human 
liver cancer. 
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CHAPTER IV  
RASSF1A PROMOTES AUTOPHAGY MATURATION BY RECRUITING 
AUTOPHAGOSOMES ONTO RASSF1A-STABILIZED ACETYLATED 
MICROTUBULES THROUGH MAP1S   
 
Introduction  
Autophagy, an evolutionarily conserved catabolic process, functions in the 
turnover of protein aggregates and damaged organelles through the lysosomal 
degradation pathway. After autophagy is initiated, the target substrates are 
captured by the phagophore to form autophagosomes which then fuse with 
lysosomes for degradation. Once autophagy is initiated, the cytosolic LC3 
undergoes lipidation by conjugating with membrane component 
phosphatidylethanolamine (PE) (12). The PE-conjugated LC3 (LC3-II) directs 
phagophore membrane to sequester target cargo by directly binding with the 
cargo receptors, such as p62/SQSTM1, NBR1, NDP52 and BNIP3L/NIX (14,97-
101). These cargo receptors specifically recognize and bind to the substrates. 
Meanwhile, the LC3-interacting region (LIR) in these cargo receptors mediates 
their interaction with autophagosome-associated LC3-II. Thus, the three-way 
interactions of cargo receptors with LC3-II and substrates enable the substrates 
to be targeted and packaged by phagophore to form autophagosomes. 
Autophagosome-anchored LC3-II bridges the mature autophagosomes with 
microtubules for trafficking. There are regular non-acetylated and stable 
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acetylated microtubules in cells and acetylated microtubules have been 
demonstrated to serve as the tracks for movement of mature autophagosomes 
and bring autophagosomes and lysosomes together for fusion to form 
autolysosomes (102). Finally, LC3-II as well as captured substrates are degraded 
in lysosomes.   
Our previous studies showed that MAP1S, a microtubule-associated 
protein, interacts with LC3-II to facilitate its association with microtubules (47), so 
that LC3-II-associated mature autophagosomes are recruited onto microtubules 
for migration (103,104). Stabilized acetylated microtubules are required for the 
trafficking and fusion of autophagosomes with lysosomes (102). It is well 
documented that RASSF1A associates with and stabilizes microtubules and 
RASSF1A was reported to stabilize microtubules by enhancing the acetylation of 
α-tubulin (31,52,54). In addition, we previously reported that MAP1S associates 
with microtubules stabilized by RASSF1A (54). Based on these reports, we 
reasoned that RASSF1A may enhance the acetylation of microtubules and recruit 
LC3-II-associated autophagosomes onto RASSF1A-stablized acetylated 
microtubules through its interactive protein MAP1S to promote autophagy 
maturation. Indeed, here we show that RASSF1A promotes the acetylation of 
microtubules by inhibiting the deacetylase activity of RASSF1A-interactive 
HDAC6, and recruits LC3-II- associated autophagosomes onto RASSF1A-
stablized acetylated microtubules through its interactive protein MAP1S. 
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Materials and Methods 
Animals 
All animal protocols were approved by the Institutional Animal Care and 
Use Committee (IACUC), Institute of Biosciences and Technology, Texas A&M 
Health Science Center. All animals received humane care according to the criteria 
outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by 
the National Academy of Sciences and published by the National Institutes of 
Health (NIH publication 86-23 revised 1985). C57BL/6 wild-type and RASSF1A-/- 
mice were bred and genotyped as described (56). Liver tissues were frozen 
immediately after mice were euthanized by CO2 asphyxiation for further analyses. 
 
Cell Culture 
HeLa, human embryonic kidney (HEK)-293T and mouse embryonic 
fibroblast (MEF) cells were cultured in DMEM medium containing 10% FBS and 
antibiotics. Primary mouse hepatocytes were cultured in William’s E culture 
medium with 10% FBS, antibiotics, Insulin-Transferrin-Selenium (ITS-G) and 
dexamethasone. PBS of pH 7.4 and 0.25% trypsin were used for subculture. All 
cells were cultured in a tissue culture incubator at 37°C with 5% CO2. 
 
Plasmid Construction 
HA-RASSF1A in pcDNA3.1 was kindly supplied by Dr. John Minna. RFP- 
LC3 and GFP-LC3 were kindly supplied by Dr. Mizushima. The construction of 
 53 
 
GFP-RASSF1A, HA-MAP1S isoforms (HA-FL, HA-HC, HA-SC and HA-LC), GFP-
MAP1S full length, R653-Q855 fragment of MAP1S in HA-PCMV plasmid (HA-
HBD), HA-MAP1S with R653-Q855 fragment deleted (HA-FLΔ) were described 
previously (53,54,105). Plasmid encoding Myc-LC3 (Addgene, #24919) and 
HDAC6 (Addgene, #30482) were purchased from Addgene. Four fragments of 
RASSF1A (F1, F2, F3 and F4) were PCR-amplified by using HA-RASSF1A as a 
template, digested with XhoI and BamHI, and ligated with pEGFP-C3 vector 
(Addgene, #6082-1) digested with XhoI and BamHI similarly as we previously 
described (53). The primers used for amplifying F1 (fragment from amino acid 1-
151), F2 (fragment from amino acid 152-186), F3 (fragment from amino acid 187-
287) and F4 (fragment from amino acid 288-340) were listed in Table 3. Sequence 
verification was performed by GENEWIZ. To construct the plasmid HA-RAΔ 
encoding RASSF1A with the RA domain (from187aa-287aa) deleted, a pair of 
primers listed in Table 3 were first phosphorylated with T4 polynucleotide kinase. 
HA-RASSF1A plasmid was then used as a template to PCR-amplify the HA-RAΔ 
by using the KOD hot start DNA polymerase from TOYOBO. After amplification, 
HA-RASSF1A template was digested by the restriction enzyme DpnI. Finally, the 
PCR product was ligated by T4 DNA Ligase (New England Biolabs, #M0202) to 
become a circular plasmid which was verified by DNA sequencing. 
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Table 3. Primers used for plasmid construction. 
 
 
 
Cell Transfection 
HeLa, HEK-293T and MEF cells were used for transient transfection. HeLa 
and MEF cells were transfected with control vectors or plasmids encoding specific 
genes by Lipofectamine 2000 according to the manufacturer’s instruction. HEK-
293T cells were transfected with control vectors or plasmids encoding specific 
genes by using calcium phosphate mammalian transfection kit (Clontech, 
#631312) according to the manufacturer’s instruction. The total proteins were 
harvested at 24 hours after transfection. 
 
Western Blotting 
Cells or mouse tissues were lysed in lysis buffer with 1 mM PMSF and 
protease inhibitor cocktail on ice. The protein concentration was determined by 
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using BCA protein assay kit. The lysates mixed with SDS loading buffer were then 
boiled for 10 minutes. Lysates containing the equal amounts of protein were 
separated by SDS-PAGE gels and transferred onto PVDF membranes. The 
membranes were blocked with 5% (w/v) non-fat milk in TBST for 1 hour at room 
temperature and then incubated with primary antibodies overnight at 4°C. The 
primary antibodies and the dilutions are: anti-RASSF1A (Abcam, #ab23950), 
1:1000; anti-HA (Covance, #MMS-101P), 1:1000; anti-Acetylated-α-tubulin 
(Santa Cruz, #23950), 1:1000; anti-HDAC6 (Santa Cruz, #11420), 1:1000; anti-
Flag (Sigma, #F3165), 1:2000; anti-Myc-Tag (Cell Signaling, #2276), 1:1000; and 
anti-GFP (Santa Cruz, #8334), 1:1000; anti-β-Actin, (Santa Cruz, #47778), 
1:2000; anti-GAPDH (Santa Cruz, #25778), 1:2000; anti-MAP1S mouse 
monoclonal antibody 4G1 was kindly supplied by Dr. Joe Corvera (A&G 
Pharmaceuticals, Inc., Columbia, MD). After being washed with the TBST buffer 
to remove nonspecific antibodies, the membranes were then incubated with HRP-
conjugated secondary antibodies for 1 hours at room temperature. After being 
washed with the TBST buffer to remove the unbound antibodies, the specifically 
bound antibodies were detected by using ECL Prime Western Blotting Detection 
Reagents. The membranes were then imaged by exposing to X-ray films. Finally, 
the relative intensity of a band to the internal control was measured by using the 
ImageJ software (NIH). 
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Co-immunoprecipitation (IP) 
To study the interaction between two proteins, the plasmids expressing 
specific proteins were co-transfected into HEK-293T or MEF cells. Cells were then 
lysed in NP-40 buffer (50 mM Tris-Hcl, pH 7.4, 150 mM NaCl, 5 mM EDTA, pH 
7.4, 1% NP-40) with 1 mM PMSF and protease inhibitor cocktails at 24 hours after 
transfection. The supernatants were collected after centrifugation and incubated 
with 1.5 µg correspondent antibodies or control IgG at 4 °C for 1.5 hours. The 
antibodies and control IgG are: anti-RASSF1A (eBioscience, #14-6888-82); anti-
LC3 (Novus Biologicals, #NB100-2331); normal mouse control IgG (Santa Cruz, 
#2025); normal rabbit control IgG (Santa Cruz, #2027) and anti-MAP1S mouse 
monoclonal antibody 4G1 was kindly supplied by Dr. Joe Corvera. After 
incubation, 20 µl Protein G-Sepharose beads (GE Health, #17-0618-01) were 
added and incubated at 4 °C for another 1.5 hours. After incubation, the beads 
were extensively washed with NP-40 buffer for five times. Finally, the precipitates 
were mixed with 100 µl lysis buffer containing SDS loading buffer, boiled in water 
for 10 minutes and analyzed by Western blotting. 
 
Fluorescent Confocal Microscopy 
HeLa cells were transfected with plasmids encoding specific genes, and 
then fixed with 4% (w/v) paraformaldehyde in PBS (prewarmed to 37 °C) for 30 
minutes at 24 hours after transfection, and blocked with 1% Bovine Serum 
Albumin (BSA) (EMD Millipore, #2960) in PBS for 20 minutes. Cells were then 
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incubated with primary antibodies for 1 hour at room temperature. The primary 
antibodies and the dilutions are: anti-HA (Cell Signaling, #3724), 1:1000; anti-
Acetylated-α-tubulin (Santa Cruze, #23950), 1:200. After extensive washing with 
PBS, cells were then incubated with corresponding secondary antibodies 
(Invitrogen, #A21202, #R-6394, dilution 1:400) for 1 hour at room temperature for 
fluorescence microscopy analysis. Images were captured with a Zeiss LSM 510 
Meta Confocal Microscope. 
 
Isolation of Primary Mouse Hepatocytes 
Mouse primary hepatocytes were isolated from 12-week-old male wild-type 
mice (RASSF1A+/+) and RASSF1A knockout mice (RASSF1A-/-) by the two-
steps liver perfusion method as previously described (57). Briefly, mice were 
anesthetized and the portal vein was catheterized after cutting open the abdomen. 
Then the liver was first perfused in situ with Earle’s Balanced Salt Solution (EBSS) 
containing 0.5 mM EGTA for 8-10 min with the inferior vena cava cut and then 
perfused for 5 min with Hanks’ Balanced Salt Solution (HBSS) supplemented with 
0.3mg/ml type IV collagenase. After perfusion, the liver was extirpated, transferred 
into plates filled with DMEM, removed of gallbladder and gently squeezed to help 
hepatocytes detach. Then cell suspension was filtered through sterile 70 μm cell 
strainers, washed by centrifugation at 600 rpm for 2 min at RT, resuspended in 
Percoll/10XHBSS (9:1) mixture and centrifuged at 600 rpm for 15 min at RT. Cell 
 58 
 
viability was examined by Trypan Blue staining. After centrifugation, pellet was 
washed and seeded at dish. 
 
Statistical Analysis 
Statistically significant effects were examined using Student’s t-test. A P 
value of less than 0.05 was considered significant and significance were set to *, 
p≤0.05; **, P≤0.01; and ***, P≤0.001. Error bars represent standard deviation. 
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Results 
RASSF1A Deletion Causes Reduced Levels of Acetylated Microtubules in Mouse 
Livers 
RASSF1A associates with and stabilizes microtubules (29,52,54). It is 
reported that RASSF1A stabilizes microtubules by promoting the acetylation of α-
tubulin (31). Stabilized acetylated microtubules are required for the trafficking and 
fusion of autophagosomes with lysosomes (102). To understand the molecular 
mechanism by which RASSF1A regulates autophagy activity, we first examined 
the impact of RASSF1A on the acetylation of microtubules in mouse livers. We 
found that RASSF1A deletion caused a reduction in levels of acetylated α-tubulin 
in mouse liver tissues (Figure 11A, B). The result was then confirmed in isolated 
primary hepatocytes from wild-type and RASSF1A-/- mice (Figure 11C, D). 
Therefore, RASSF1A deletion suppresses microtubular acetylation in mouse liver 
tissues. 
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RASSF1A Associates with Acetylated Microtubules 
Then we examined the subcellular distribution of RASSF1A and acetylated 
microtubules. Consistent with previous report, overexpressed RASSF1A did 
greatly enhance the acetylation of α-tubulin (Figure 12A, B) (31). In addition, as 
shown in the fluorescent images, RASSF1A colocalized with acetylated α-tubulin 
(Figure 12C, D). Therefore, RASSF1A not only enhances acetylation of 
microtubules but also associates with acetylated microtubules. 
 
Figure 11. RASSF1A deletion causes reduced levels of acetylated α-
tubulin in mouse livers. (A, B) Immunoblot analysis (A) and 
quantification (B) of levels of acetylated α-tubulin in liver tissues from 4-
month-old wild-type and RASSF1A-/- mice. (C, D) Immunoblot analysis (C) 
and quantification (D) of levels of acetylated α-tubulin in primary 
hepatocytes isolated from wild-type and RASSF1A-/- mice. *, P ≤ 0.05. 
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RASSF1A Interacts with Histone Deacetylase 6 (HDAC6) 
Histone deacetylase 6 (HDAC6), a member of the histone deacetylase 
family, is localized primarily in the cytoplasm and associates with microtubules to 
Figure 12. RASSF1A enhances the acetylation of α-tubulin and 
associates with acetylated α-tubulin. (A, B) Immunoblot analysis (A) and 
quantification (B) of levels of acetylated α-tubulin in HeLa cells transiently 
transfected with control plasmid (Ctrl) or plasmid expressing HA-RASSF1A 
(HA-RA). (C) Representative fluorescent images showing the 
colocalization (yellow) of RASSF1A (red) with acetylated microtubules 
(green) in cells similar to those in (A). Scale bar, 20µM. (D) Quantification 
of the immunostaining intensities of acetylated α-tubulin as shown in (C). 
**, P ≤ 0.01.  
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function as the tubulin deacetylase (106). RASSF1A is reported to impair HDAC6 
deacetylase activity on α-tubulin, but the underneath mechanism is unknown (31). 
We showed here that RASSF1A did have no effect on protein levels of HDAC6 as 
reported (Figure 13A) (31). However, we found that RASSF1A-specific antibody 
could pull down the exogenous or endogenous RASSF1A together with 
overexpressed HDAC6 (Figure 13B, C). The RASSF1A-HDAC6 interaction may 
result in an impairment of HDAC6 deacetylase activity on α-tubulin. Therefore, 
RASSF1A interacts with HDAC6 to inhibit its deacetylase activity to enhance 
microtubular acetylation. 
 
 
 
 
Figure 13. RASSF1A interacts with HDAC6. (A, B) Immunoblot analysis 
(A) and quantification (B) of HDAC6 levels in cells transiently transfected 
with control plasmid (Ctrl) or plasmid expressing HA-RASSF1A (HA-RA). 
(C, D) RASSF1A interacts with HDAC6. Lysates from 293T cells transiently 
overexpressing HA-RASSF1A and Flag-HDAC6 were precipitated with a 
HA‐specific antibody or IgG control antibody (C). Lysates from HeLa cells 
transiently overexpressing Flag-HDAC6 were precipitated with RASSF1A-
specific antibody or IgG control antibody (D).   
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RASSF1A Interacts with LC3-II 
Autophagosome-associated LC3-II serves as a linker to bridge cargo-
containing autophagosomes with microtubules for trafficking. Mass spectrometry 
analysis showed that RASSF1 associates with LC3 (107), which triggers us to 
hypothesize that RASSF1A interacts with LC3-II and helps recruit LC3-II-
associated autophagosomes onto acetylated microtubules to promote autophagy 
maturation. Expectedly, as shown by the immunoprecipitation analysis, 
RASSF1A-specific antibody co-precipitated the overexpressed RASSF1A with the 
overexpressed Myc-LC3-II in HEK-293T cells (Figure 14B). Further studies 
showed that the RA domain in RASSF1A mediated its interaction with LC3-II 
(Figure 14A, C). Therefore, RASSF1A interacts with LC3-II, which further 
indicates that RASSF1A may recruit autophagosomes onto acetylated 
microtubules to promote autophagy maturation. 
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Figure 14. RASSF1A interacts with LC3-II. (A) A diagram showing the 
domain structure of RASSF1A protein and its mutant constructs. RASSF1A 
contains four characterized domains: C1, phorbol ester/diacylglycerol 
binding domain; ATM, ataxia-telangiectasia mutated domain; RA*, Ras-
association (RalGDS/AF-6) domain; SARAH, Mst and Sav1 binding 
domain. Four fragments of RASSF1A (F1, F2, F3 and F4) were fused with 
GFP, respectively. (B) Immunoblot analysis showing the interaction 
between RASSF1A and LC3-II in MEFs transiently expressing HA-
RASSF1A and Myc-LC3. Cell lysates were precipitated with a HA‐specific 
antibody or IgG control antibody. (C) LC3-II interacts with RA domain in 
RASSF1A. Lysates from 293T cells transiently expressing GFP-LC3 and 
GFP fused RASSF1A constructs were precipitated with LC3‐specific 
antibody or IgG control antibody. 
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RASSF1A Interacts with Microtubule-associated Protein 1s (MAP1S) 
Autophagy activator MAP1S interacts with autophagosome-associated 
LC3 and bridges autophagosomes with microtubules for trafficking (47). We 
reported that RASSF1A stabilizes microtubules and recruits MAP1S onto the 
stabilized microtubules, and RASSF1A recruits LC3 on RASSF1A-stabilized 
microtubules only in cells transiently expressing MAP1S-SC (47,54). The previous 
studies triggered us to hypothesize that RASSF1A recruits LC3-II-associated 
autophagosomes onto RASSF1A-stabilized acetylated microtubules through 
MAP1S. To test this hypothesis, we first examined whether RASSF1A interacts 
with MAP1S by performing immunoprecipitation analysis. Results showed that 
RASSF1A interacted with full length (FL), heavy chain (HC) and short chain (SC) 
but not light chain (LC) of MAP1S (Figure 15B, C, D and E), suggesting that the 
overlapping region between HC and SC (from R653 to Q855) in MAP1S is the 
potential binding domain for RASSF1A. This region has been identified as the 
HDAC4-binding domain (HBD) (105). Expectedly, RASSF1A pulled down the HA-
fused R653 to Q855 fragment of MAP1S (HA-HBD), and in turn HA-HBD also 
pulled down RASSF1A (Figure 15F, G). Deletion of HBD domain from MAP1S 
(HA-FL∆) abolished the interaction between MAP1S and RASSF1A (Figure 15H). 
Therefore, RASSF1A interacts with MAP1S. 
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Figure 15. RASSF1A interacts with MAP1S via the overlapping 
domain between heavy chain (HC) and short chain (SC) of MAP1S. (A) 
A diagram showing the domain structure of MAP1S protein. FL (full length), 
HC (heavy chain), SC (short chain), LC (light chain). 4G1, region 
recognized by MAP1S monoclonal antibody 4G1; HBD, HDAC4‐binding 
domain (the overlapping domain (R653-Q855) between HC and SC). (B-
E) RASSF1A interacts with MAP1S isoforms FL (B), HC (C) and SC (D) 
but not LC (E). Lysates from 293T cells transiently expressing HA-
RASSF1A and HA‐fused MAP1S isoforms were precipitated with MAP1S‐
specific 4G1 antibody, or RASSF1A-specific antibody, or IgG control. (F, 
G) RASSF1A interacts with the HBD domain of MAP1S. Lysates from 293T 
cells transiently expressing HA-RASSF1A and HA‐fused HBD domain of 
MAP1S (HA‐HBD) were precipitated with RASSF1A‐specific antibody, or 
MAP1S‐specific 4G1 antibody, or IgG control. (H) MAP1S-FL with the HBD 
domain deleted (FLΔ) does not interact with RASSF1A. Lysates from 293T 
cells transiently expressing HA-RASSF1A and HA-fused MAP1S FL (HA-
FL) or HA‐fused FLΔ (HA- FLΔ) were precipitated with RASSF1A‐specific 
antibody or IgG control.  
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RASSF1A Interacts with MAP1S via The RA Domain 
Next, we examined which domain in RASSF1A mediates its interaction with 
MAP1S. Immunoprecipitation analysis showed that MAP1S-specific antibody co-
precipitated the endogenous MAP1S with the overexpressed RA domain of 
RASSF1A (Figure 16A). Deletion of RA domain from RASSF1A resulted in the 
abolishment of its interaction with MAP1S (Figure 16B). Therefore, RA domain in 
RASSF1A mediates its interaction with MAP1S. 
 
 
 
 
 
 
 
Figure 16. RASSF1A interacts with MAP1S via the RA domain. (A) 
MAP1S interacts with the RA domain in RASSF1A. Lysates from 293T cells 
transiently expressing GFP, or GFP fused RASSF1A fragments were 
precipitated with MAP1S‐specific 4G1 antibody or IgG control. (B) 
RASSF1A with RA domain deleted (RAΔ) does not interact with MAP1S. 
Lysates from 293T cells transiently expressing HA-FL and HA-RASSF1A 
or HA-fused RAΔ (HA-RAΔ) were precipitated with MAP1S‐specific 4G1 
antibody or IgG control.  
 
 
 
 
 
 
 
 68 
 
The Interaction between RASSF1A and LC3-II Requires MAP1S 
To further test our hypothesis that RASSF1A recruits LC3-II-associated 
autophagosomes onto RASSF1A-stabilized acetylated microtubules through 
MAP1S, we then examined whether the interaction of RASSF1A with LC3-II 
requires MAP1S. The immunoprecipitation analysis showed that in wild-type 
MEFs cells, but not in MAP1S knockout MEFs cells, RASSF1A-specific antibody 
co-precipitated the overexpressed RASSF1A with the overexpressed Myc-LC3-II 
and endogenous MAP1S (Figure 17A), indicating that RASSF1A interacts with 
LC3-II in a MAP1S-dependent manner. To confirm it, HA-RASSF1A, Myc-LC3 
and HA-FL were transiently co-transfected into HEK-293T cells and the 
immunoprecipitation analysis were performed. We found that RASSF1A pulled 
down more LC3-II in cells transiently expressing HA-FL, but not HA-FL∆ which 
has no interaction with RASSF1A (Figure 17A). Therefore, RASSF1A, MAP1S 
and LC3-II form a complex, and the association between RASSF1A and LC3-II 
requires MAP1S. 
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Figure 17. The interaction of RASSF1A with LC3-II requires MAP1S. 
(A) The interaction between RASSF1A and LC3-II requires MAP1S. 
Lysates from wild-type and MAP1S-deleted MEFs transiently expressing 
HA-RASSF1A and Myc-LC3 were precipitated with RASSF1A‐specific 
antibody or IgG control. (B) MAP1S, but not HBD domain deleted MAP1S, 
promotes the association between RASSF1A and LC3-II. Lysates from 
293T cells transiently expressing HA-RASSF1A, Myc-LC3 and HA, or HA-
FL, or HA- FLΔ were precipitated with RASSF1A‐specific antibody or IgG 
control. 
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RASSF1A Recruits Autophagosomes onto Acetylated Microtubules through 
MAP1S 
To examine whether RASSF1A recruits LC3-II-associated 
autophagosomes onto acetylated microtubules through MAP1S, we then 
performed the immunofluorescent staining analysis. The images showed that 
without RASSF1A, overexpressed MAP1S was detected diffusely in the 
cytoplasm. However, overexpressed RASSF1A not only enhanced the acetylation 
of microtubules, but also recruited MAP1S onto acetylated microtubules (Figure 
18A). Further analysis showed that overexpressed RASSF1A recruited MAP1S 
and then LC3 onto acetylated microtubules (Figure 18B). Taken together, 
RASSF1A enhances microtubular acetylation and then recruits LC3-II-associated 
autophagosomes onto acetylated microtubules through LC3-II-interactive MAP1S 
to promote autophagy maturation (Figure 18C). 
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Figure 18. RASSF1A recruits autophagosomes onto RASSF1A-
stabilized acetylated microtubules through MAP1S. (A) Representative 
fluorescent images show that RASSF1A recruits MAP1S onto RASSF1A-
stabilized acetylated microtubules. Scale bar, 10 µM. (B) Representative 
fluorescent images show that RASSF1A greatly promotes the co-
localization of MAP1S and LC3 on acetylated microtubules. Scale bar, 10 
µM. (C) A diagram showing the mechanism by which RASSF1A promotes 
autophagy maturation. RASSF1A enhances microtubular acetylation and 
associates with acetylated microtubules. Meanwhile, RASSF1A interacts 
with MAP1S and thereby recruits LC3-II-associated autophagosomes onto 
acetylated microtubules to promote autophagy maturation.  
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Discussion 
In previous chapters, we show that RASSF1A deletion leads to autophagy 
defects in mouse livers which promote hepatocarcinogenesis induced by chemical 
carcinogen DEN. However, the underlying mechanism by which RASSF1A 
regulates autophagy is unknown. In this chapter, we found that RASSF1A 
promotes autophagy maturation by recruiting LC3-II-associated autophagosomes 
onto RASSF1A-stabilized acetylated microtubules through MAP1S.  
In 2000, LC3 was identified as the first mammalian protein that is 
specifically localized in autophagosomal membranes (12). The autophagosomal-
anchored LC3 (LC3-II) functions in autophagosomal trafficking by linking 
autophagosomes to microtubules. MAP1S, a microtubule-associated autophagy 
activator, promotes autophagosomal trafficking on microtubules by directly 
interacting with LC3 (47). Because RASSF1A interacts with MAP1S, we expected 
that RASSF1A would regulate autophagy maturation through MAP1S. As 
expected, RASSF1A interacts autophagosome-associated LC3-II in a MAP1S-
dependent manner and RASSF1A recruits MAP1S and LC3-II onto RASSF1A-
stabilized acetylated microtubules, indicating that RASSF1A promotes MAP1S-
mediated autophagosomal trafficking.  
Microtubules, filamentous intracellular structures, are formed by the 
polymerization of α-tubulin and β-tubulin heterodimers. The constant 
polymerization and depolymerization of microtubules are regulated by 
microtubule-associated proteins (108,109). Microtubule dynamics play an 
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essential role in the movement of intracellular vesicles, organelles and 
macromolecular assemblies (110). In the past decade, studies have 
demonstrated that microtubules are also implicated in several steps of the 
dynamic autophagy process, including autophagosomal initiation, maturation and 
fusion with lysosomes (102-104). Regular non-acetylated microtubules are 
involved in, but not essential for autophagosomal formation, as evidenced by the 
still existence but a significantly decreased ratio of autophagosomal biogenesis or 
the LC3-I to LC3-II conversion in the absence of the intact regular microtubules. 
Regular non-acetylated microtubules are not involved in the process of fusion of 
autophagosomes with lysosomes, because there is no accumulation of LC3-II with 
their interruption (103,104). Acetylated microtubules are required for trafficking 
and fusion of mature autophagosomes with lysosomes which also move along 
microtubules to distribute throughout the cytoplasm (102,111,112). Disruption of 
both non-acetylated and acetylated microtubules impairs the conversion of LC3-I 
to LC3-II and the autophagosomal degradation (102). RASSF1A enhances 
microtubular acetylation and recruits autophagosomes onto the acetylated 
microtubules where autophagosomes are delivered to fuse with lysosomes and 
the captured substrates as well as LC3-II are degraded. Therefore, without 
RASSF1A, cargo-containing autophagosomes are not recruited onto 
microtubules for trafficking and fusion with lysosomes, which causes the 
accumulation of protein aggregates and dysfunctional organelles such as 
mitochondria to enhance oxidative stresses and genome instability. In addition to 
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serve as tracks for autophagosomal trafficking, microtubules also play an 
essential role in regulating the progress of cell cycle and cellular migration. High 
level of RASSF1A maintains microtubules in stabilized state so that during mitosis, 
RASSF1A localizes to centrosomes, spindle microtubules and spindle poles to 
arrest mitosis and promote cell death (113). The ability to stabilize microtubules 
also allows RASSF1A to suppress cellular migration (31). Therefore, level of 
RASSF1A in cells plays an essential role in mediating the decision to promote 
autophagy or cell death.  
Although RASSF1A enhances acetylation of α-tubulin, the underlying 
mechanism is unclear. The acetylation of α-tubulin at K40 is a hallmark of stable 
microtubules. α-tubulin acetyl-transferase (α-TAT) is known to transfer an acetyl 
group from acetyl-CoA to K40 of α-tubulin and histone deacetylase (HDAC6) 
functions as the α-tubulin deacetylase (106,114). Although RASSF1A has no 
impact on protein levels of HDAC6, we show here that RASSF1A interacts with 
HDAC6. We predict that RASSF1A may bind to HDAC6 enzymatic domain and 
block its deacetylase activity, or RASSF1A may compete with HDAC6 in binding 
to microtubules, which needs to be further investigated. In addition, examining 
whether RASSF1A acts on α-TAT may also help to uncover the underlying 
mechanism.    
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CHAPTER V  
RASSF1A PROMOTES AUTOPHAGY INITIATION BY SUPPRESSING PI3K-
AKT-MTOR PATHWAY THROUGH HIPPO PATHWAY REGULATORY 
PROTEIN MST1 
 
Introduction  
Autophagy, a lysosome-mediated degradation pathway, can be rapidly 
enhanced during starvation to sustain cell metabolism by supplying necessary 
nutrients. Autophagy can also be activated during stresses to protect cells through 
eliminating damaged organelles and proteins that accumulate in the cytoplasm. It 
is well established that mTOR is a major negative regulator of autophagy initiation 
(115,116). In the presence of growth factors, mTOR, a serine/threonine kinase, 
can be activated by the receptor tyrosine kinase (RTK)-class I PI3K-Akt signaling 
pathway. Specifically, the activated Akt first directly phosphorylates the tuberous 
sclerosis (TSC) tumor suppressor complex (TSC1/TSC2) which is the most 
important upstream negative regulator of mTOR (117,118). The phosphorylated 
TSC1/2 then rapidly dissociate from lysosomal surface (119). TSC1/2 is a 
GTPase-activating protein (GAP) for the Ras homolog enriched in brain (Rheb) 
GTPase (120). Therefore, the Rheb localized on lysosome is subsequently turned 
on. GTP-bound Rheb, an essential mTOR activator, then activates mTOR (121). 
The activated mTOR phosphorylates the downstream effector autophagy-
initiating kinase Ulk1 (a homologue of yeast ATG1) to suppress autophagy 
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initiation. The relationship between mTOR and ATG1 complex has been well 
studied in yeast. mTOR can directly phosphorylate ATG13, a critical component 
of the ATG1 complex, and thereby prevent ATG13 from forming the complex with 
ATG1 (122-124). It is reported that, in mammalian cells, the activated mTOR can 
inhibit Ulk1 activation by phosphorylating Ulk1 at Ser 757 (125).  
Microtubule-associated protein 1 small form (MAP1S), a homologue of 
neuron-specific MAP1A/B, is demonstrated to regulate autophagy initiation 
through Bcl-2/xL enhanced p27-mediated non-canonical autophagy pathway (47). 
In addition to anti-apoptotic roles, B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-
extra large (Bcl-xL) exhibit the opposite roles in autophagy initiation. Under normal 
conditions, Bcl-2/Xl can bind to Beclin1 and prevent Beclin1 (a homologue of yeast 
ATG6) from interacting with class III PI3K to form class III PI3K complex which is 
responsible for the phagophore nucleation. Thus, the Beclin-1 dependent 
autophagy initiation is inhibited. Bcl-2/xL can also activate autophagy initiation by 
increasing the levels of cyclin-dependent kinase inhibitor 1B (p27) which elevates 
ATG5 levels to activate autophagy through a Beclin1-independent autophagy 
pathway (48,126,127). Our previous studies showed that MAP1S deletion in mice 
causes a reduced autophagy flux along with the decreased levels of Bcl-2/xL and 
p27, but no alteration in Akt-mTOR activity, suggesting that MAP1S sustains Bcl-
2/xL and p27 levels to enhance autophagy initiation (47).  
In chapter I, we show that RASSF1A depletion results in a significant 
reduction in levels of LC3-II in the presence of lysosomal inhibitor, indicating a 
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reduction in autophagy initiation due to RASSF1A depletion. However, the 
underlying mechanism by which RASSF1A regulates autophagy initiation has not 
been elucidated. The direct interaction of RASSF1A with autophagy activator 
MAP1S triggered us to reason that RASSF1A may regulate autophagy initiation 
through MAP1S. However, here we show that RASSF1A does not regulate 
autophagy initiation in the same way as MAP1S does. RASSF1A interacts with 
Hippo pathway regulator Mst1 and stabilizes Mst1 to suppress PI3K-Akt-mTOR 
pathway to promote autophagy initiation.     
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Materials and Methods 
Animals 
All animal protocols were approved by the Institutional Animal Care and 
Use Committee (IACUC), Institute of Biosciences and Technology, Texas A&M 
Health Science Center. All animals received humane care according to the criteria 
outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by 
the National Academy of Sciences and published by the National Institutes of 
Health (NIH publication 86-23 revised 1985). C57BL/6 wild-type and RASSF1A-/- 
mice were bred and genotyped as described (56). Liver tissues were frozen 
immediately after mice were euthanized by CO2 asphyxiation for further analyses. 
  
Cell Culture 
HeLa and MEFs cells were cultured in DMEM medium containing 10% FBS 
and antibiotics. PBS of pH 7.4 and 0.25% trypsin were used for subculture. All 
cells were cultured in a tissue culture incubator at 37°C with 5% CO2. 
 
siRNA and Cell Transfection 
HeLa cells were transfected with random or RASSF1A-specific siRNA 
molecules by using Oligofectamine according to the manufacturer’s 
recommended instruction. The total proteins were harvested at 48 hours after 
transfection. HeLa cells were transfected with control vector or plasmid encoding 
p27 gene (Addgene, #14049) by Lipofectamine 2000 according to the 
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manufacturer’s instruction. The total proteins were harvested at 24 hours after 
transfection. 
 
Western Blotting 
Cells or mouse tissues were lysed in lysis buffer with 1 mM PMSF and 
protease inhibitor cocktail on ice. The protein concentration was determined by 
using BCA protein assay kit. The lysates mixed with SDS loading buffer were then 
boiled for 10 minutes. Lysates containing the equal amounts of protein were 
separated by SDS-PAGE gels and transferred onto PVDF membranes. The 
membranes were blocked with 5% (w/v) non-fat milk in TBST for 1 hour at room 
temperature and then incubated with primary antibodies overnight at 4°C. The 
primary antibodies and the dilutions are: anti-RASSF1A (Abcam, #ab23950), 
1:1000; anti-HDAC4 (Cell Signaling, #7628S), 1:1000; anti-Bcl-2 (Santa Cruz, 
#7382), 1:1000; anti-p27 (Santa Cruz, #528), 1:1000; anti-Acetyl-lysine (EMD 
Millipore, #05515), 1:1000; anti-Flag (Sigma, #F3165), 1:1000; anti-p-Akt (Cell 
Signaling, #2965S), 1:1000; anti-Akt (Santa Cruz,, #5298), 1:1000; anti-p-MST1 
(Cell Signaling, #3681S), 1:1000; anti-MST1 (Proteintech, #22245-1-AP), 1:1000; 
anti-p-S6K (Cell Signaling, #9205S), 1:1000; anti-LC3 (Novus Biologicals, 
#NB100-2331), 1:1000; anti-Yap (Cell Signaling, #4912S), 1:1000; anti-p-Yap 
(Cell Signaling, #4911S), 1:1000; anti-CTGF (Abcam, #ab6992), 1:1000; anti-
GAPDH (Santa Cruz, #25778), 1:1000; anti-β-Actin (Santa Cruz, #47778), 
1:2000; anti-MAP1S mouse monoclonal antibody 4G1 was kindly supplied by Dr. 
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Joe Corvera (A&G Pharmaceuticals, Inc., Columbia, MD). After being washed 
with the TBST buffer to remove nonspecific antibodies, the membranes were then 
incubated with HRP-conjugated secondary antibodies for 1 hours at room 
temperature. After being washed with the TBST buffer to remove the unbound 
antibodies, the specifically bound antibodies were detected by using ECL Prime 
Western Blotting Detection Reagents. The membranes were then imaged by 
exposing to X-ray films. Finally, the relative intensity of a band to the internal 
control was measured by using the ImageJ software (NIH). 
 
Co-immunoprecipitation (IP) 
To study the interaction between two proteins or the acetylation levels of 
one protein, cells or liver tissues were first lysed in NP-40 buffer with 1 mM PMSF 
and protease inhibitor cocktails. The supernatants were collected after 
centrifugation and incubated with 1.5 µg correspondent antibodies or control IgG 
at 4 °C for 1.5 hours. The antibodies and control IgG are: anti-Acetyl-lysine (EMD 
Millipore, #05515); anti-RASSF1A (eBioscience, #14-6888-82); anti-Akt (Santa 
Cruz, #5298); normal mouse control IgG (Santa Cruz, #2025); and anti-MAP1S 
mouse monoclonal antibody 4G1 was kindly supplied by Dr. Joe Corvera. After 
incubation, 20 µl protein G-Sepharose beads (GE Health, #17-0618-01) were 
added and incubated at 4 °C for another 1.5 hours. After incubation, the beads 
were extensively washed with NP-40 buffer for five times. Finally, the precipitates 
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were mixed with 100 µl lysis buffer containing SDS loading buffer, boiled in water 
for 10 minutes and analyzed by Western blotting. 
 
Establishment of Mouse Embryonic Fibroblasts (MEFs) 
Mouse embryonic fibroblasts were prepared from wild-type (RASSF1A+/+) 
and RASSF1A knockout mice (RASSF1A-/-) as described (47). Briefly, embryos 
collected at E12.5-14.5 were minced in DMEM medium, incubated with 0.25% 
trypsin at 37 °C for 10 min and then filtered through 70 µm cell strainer. The 
separated cells were then harvested and cultured in DMEM containing 10% FBS 
and antibiotics. 
 
Statistical Analysis  
Statistically significant effects were examined using Student’s t-test. A P 
value of less than 0.05 was considered significant and significance were set to *, 
p≤0.05; **, P≤0.01; and ***, P≤0.001. Error bars represent standard deviation.   
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Results 
RASSF1A Does Not Regulate Autophagy Initiation through MAP1S in HeLa Cells 
Reduced LC3-II levels in RASSF1A-suppressed HeLa cells, RASSF1A-
deleted MEFs, mouse hepatocytes and mouse liver tissues (Figure 3, 4, 5) 
indicate that RASSF1A depletion causes a reduction in autophagy initiation. The 
interaction between RASSF1A and autophagy activator MAP1S triggered us to 
examine whether RASSF1A directly regulates MAP1S to affect MAP1S-mediated 
autophagy initiation. Our lab previously reported that MAP1S sustains levels of 
Bcl-2/xL which increase p27 levels to enhance p27-mediated autophagy initiation 
(47,48). Acetylated MAP1S plays an essential role in promoting autophagy. 
Mammalian histone deacetylase 4 (HDAC4) has been demonstrated to 
deacetylate and destabilize MAP1S to suppress MAP1S-mediated autophagy 
(105). Here we found that although levels of HDAC4, Bcl-2 and p27 reduced in 
RASSFA-suppressed HeLa cells, levels of MAP1S remained constant (Figure 
19A, B and C). Moreover, levels of acetylated MAP1S were not altered in HeLa 
cells transiently expressing RASSF1A without or with HDAC4 inhibitor apicidin 
treatment (Figure 19D and E). Forced expression of p27 in RASSF1A-suppressed 
HeLa cells did not restore the reduced autophagy flux (Figure 19F, G). Taken 
together, knockdown of RASSF1A in HeLa cells results in reduced autophagy 
initiation not through MAP1S-Bcl-2-p27 non-canonical pathway. 
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Figure 19. RASSF1A has no impact on MAP1S-mediated autophagy 
initiation pathway in HeLa cells. (A-C) Immunoblot analysis (A) and 
quantification (B, C) of levels of MAP1S, HDAC4, Bcl-2 and p27 in wild-type 
and RASSF1A-suppressed HeLa cells. (D) Overexpressed RASSF1A has no 
impact on levels of acetylated MAP1S. Lysates from 293T cells transiently 
expressing HA-MAP1S and HA or HA-RASSF1A were precipitated with 
MAP1S-specific antibody and blotted with Ac-K antibody. APCD, Histone 
deacetylase inhibitor. (E) Quantification of levels of acetylated MAP1S as 
shown in (D). (F, G) Immunoblot analysis (F) and quantification (J) of LC3-II 
levels in wild-type and RASSF1A-suppressed HeLa cells transiently 
transfected with control vector or vector encoding p27 in the absence or 
presence of BAF. *, P ≤ 0.05; ns, nonsignificant, P > 0.05. 
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RASSF1A Does Not Regulate Autophagy Initiation through MAP1S in Mouse 
Livers 
Next, we examined whether RASSF1A deletion alters MAP1S-mediated 
autophagy initiation pathway in mouse livers. The immunoblot results showed that 
RASSF1A deletion had no impact on protein levels of MAP1S, HDAC4, Bcl-2 and 
p27 in mouse livers (Figure 20A, B and C). Moreover, RASSF1A deletion also did 
not alter levels of acetylated MAP1S in liver tissues from wild-type and RASSF1A-
/- mice (Figure 20D, E). Taken together, RASSF1A deletion results in reduced 
autophagy initiation in mouse livers not through MAP1S-Bcl-2-p27 non-canonical 
pathway. 
 
 
 
Figure 20. RASSF1A has no impact on MAP1S-mediated autophagy 
initiation pathway in mouse livers. (A-C) Immunoblot analysis (A) and 
quantification (B, C) of levels of MAP1S, HDAC4, Bcl-2 and p27 in liver tissues 
from wild-type and RASSF1A-/- mice. (D) RASSF1A deletion causes no change 
of levels of acetylated MAP1S. Liver tissue lysates from wild-type and 
RASSF1A-/- mice were precipitated with Ac-K-specific antibody. (E) 
Quantification of levels of acetylated MAP1S as shown in (D). ns, 
nonsignificant, P > 0.05. 
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Figure 20. Continued. 
 
 
 
RASSF1A Suppresses PI3K-Akt-mTOR Pathway to Promote Autophagy Initiation 
in HeLa Cells 
PI3K-Akt-mTOR pathway is a well-known pathway that acts as a major 
negative regulator of autophagy initiation (116,124). We found that knockdown of 
RASSF1A in HeLa cells caused increases in levels of phosphorylated Akt and 
phosphorylated S6K, a downstream effector of mTOR (Figure 21A, B, C). 
Therefore, RASSF1A suppresses PI3K-Akt-mTOR pathway in HeLa cells to 
promote autophagy initiation. 
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RASSF1A Suppresses PI3K-Akt-mTOR Pathway to Promote Autophagy Initiation 
in Mouse Livers 
Next, we examined whether RASSF1A deletion in mice also causes the 
activation of PI3K-Akt-mTOR pathway. Immunoblot results showed that 
RASSF1A deletion also caused increases in levels of phosphorylated Akt and 
phosphorylated S6K in MEFs and mouse liver tissues (Figure 22A, B, C, D, E, F). 
PI3K-Akt-mTOR pathway was also activated in DEN-treated 6-month-old liver 
tissues from RASSF1A-/- mice (Figure 22G, H, I). Therefore, RASSF1A 
suppresses PI3K-Akt-mTOR pathway in mouse livers to promote autophagy 
initiation. 
 
 
Figure 21. RASSF1A suppression causes the activation of PI3K-Akt-
mTOR pathway in HeLa cells. (A-C) Immunoblot analysis (A) and 
quantification (B, C) of levels of p-Akt and p-S6K in HeLa cells treated with 
random (Mock) or RASSF1A-specific siRNAs (RA). 
 
 87 
 
 
 
 
 
 
Figure 22. RASSF1A deletion causes the activation of PI3K-Akt-
mTOR pathway in mice. (A-C) Immunoblot analysis (A) and quantification 
(B, C) of levels of p-Akt and p-S6K in MEFs from wild-type and RASSF1A-
/- mice. (D-F) Immunoblot analysis (D) and quantification (E, F) of levels of 
p-Akt and p-S6K in liver tissues from wild-type and RASSF1A-/- mice. (G-
I) Immunoblot analysis (G) and quantification (H, I) of levels of p-Akt and 
p-S6K in liver tissues from DEN-treated 6-month-old wild-type and 
RASSF1A-/- mice.  
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RASSF1A Suppresses PI3K-Akt-mTOR Pathway to Promote Autophagy Initiation 
through Hippo Pathway Regulatory Protein Mst1  
We then examined the mechanism by which RASSF1A suppresses PI3K-
Akt-mTOR pathway. It was reported that RASSF1A maintains the stability and 
activity of Mst1 (mammalian STE20-like kinase 1) by directly interacting with Mst1 
and preventing it from dephosphorylation by PP2A (128). It was also reported that 
Mst1 acts as a direct inhibitor of Akt through directly binding to Akt (129). 
Therefore, we reasoned that RASSF1A depletion may lead to the 
dephosphorylation and instability of Mst1, resulting in a reduction in Mst1-Akt 
interaction and thereby an increase in Akt activity. We first reconfirmed that 
endogenous RASSF1A was able to pull down endogenous Mst1 as well as Akt 
(Figure 23A), and endogenous Akt was able to pull down endogenous Mst1 as 
well as RASSF1A (Figure 23B), indicating that RASSF1A, Akt and Mst1 form a 
protein complex. As expected, RASSF1A deletion did lead to decreased levels of 
phosphorylated Mst1 and total Mst1 in mouse liver tissues (Figure 23C, D and E). 
RASSF1A depletion in HeLa cells also led to a reduced level of total Mst1 so that 
the levels of Mst1 co-immunoprecipitated with Akt were dramatically decreased in 
RASSF1A-suppressed HeLa cells (Figure 23F, G). Therefore, RASSF1A 
depletion leads to the dephosphorylation and instability of Mst1, which results in 
a reduction in Mst1-Akt interaction and thereby the activation of PI3K-Akt-mTOR 
pathway to suppress autophagy initiation (Figure 23H). 
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Figure 23. RASSF1A suppresses PI3K-Akt-mTOR pathway to promote 
autophagy initiation through Hippo pathway regulatory protein Mst1. 
(A) Endogenous RASSF1A interacts with endogenous MST1 and Akt. 
Lysates from HeLa cells were precipitated with RASSF1A-specific antibody 
or IgG control. (B) Endogenous Akt interacts with endogenous Mst1 and 
RASSF1A. Lysates from HeLa cells were precipitated with Akt-specific 
antibody or IgG control. (C-E) Immunoblot analysis (C) and quantification 
(D, E) of levels of p-Mst1 and total Mst1 in liver tissues from wild-type and 
RASSF1A-/- mice. (F) RASSF1A knockdown weakens the Akt-Mst1 
interaction. Lysates from HeLa cells treated with mock or RASSF1A-
specific siRNA were precipitated with Akt-specific antibody or IgG control. 
(G) Quantification of levels of total Mst1 and coprecipitated Mst1 as shown 
in (F). (H) A diagram showing the mechanism by which RASSF1A regulates 
autophagy initiation. RASSF1A interacts with and stabilizes Mst1 by 
preventing it from dephosphorylation. Stabilized Mst1 inhibits Akt activity 
by directly interacting with Akt. Without RASSF1A, Mst1 is 
dephosphorylated and then degraded. Thus, the Akt-Mst1 interaction is 
disrupted and Akt is activated to suppress autophagy initiation.   
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RASSF1A has No Impact on Hippo Pathway in Mouse Livers 
Hippo pathway, an evolutionarily conserved pathway, controls organ size 
and tissue homeostasis by regulating cell proliferation, apoptosis, and stemness 
(130). Dysregulation of Hippo pathway leads to tumorigenesis (131,132). Since 
RASSF1A maintains the stability and activity of MST1 (Figure 23), RASSF1A was 
suggested to be an important regulator of Hippo pathway and suppress 
tumorigenesis through Hippo pathway. We then examined the impact of 
RASSF1A on the components of the Hippo pathway in mouse livers. However, 
we found that RASSF1A deletion did not alter levels of phosphorylated Yap, total 
Yap and CTGF, a direct Yap target gene (Figure 24 A, B). Therefore, at least in 
mouse liver tissues, RASSF1A deletion does not impact much the downstream 
effectors of the Hippo pathway. 
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Figure 24. RASSF1A deletion has no impact on the downstream 
effectors of Hippo pathway. (A, B) Immunoblot analysis (A) and 
quantification (B) of levels of p-Yap, total Yap and CTGF in liver tissues 
from wild-type and RASSF1A-/- mice.  
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Discussion 
Autophagy activator MAP1S regulates both autophagy initiation and 
maturation (47). In chapter IV, we showed that RASSF1A promotes autophagy 
maturation by recruiting LC3-II-associated autophagosomes onto RASSF1A-
stabilized acetylated microtubules through MAP1S. This result triggered us to 
reason that RASSF1A may regulate autophagy initiation also through MAP1S.  
Autophagy initiation is regulated through the well-known canonical PI3K-
Akt-mTOR pathway or the non-canonical LKB1-AMPK-mTOR pathway (48). In 
addition to act as a cell cycle inhibitor, p27 is able to enhance autophagy initiation 
through the LKB1-AMPK-mTOR pathway (48). MAP1S sustains the levels of Bcl-
2/xL which enhance p27 to promote autophagy initiation through LKB1-AMPK-
mTOR pathway (47,126). However, here we found that RASSF1A has no impact 
on MAP1S-Bcl-2-p27 autophagy pathway. First, RASSF1A deletion did not alter 
levels of MAP1S, Bcl-2 and p27 in mouse liver tissues. Acetylation is one of the 
important post-translational modification of MAP1S. We previously reported that 
HDAC4 directly binds to, deacetylates and destabilizes MAP1S to suppress 
autophagy flux (105) and lysine 520 of MAP1S is critical for MAP1S to enhance 
autophagosomal degradation (57), indicating that acetylated MAP1S, but not the 
non-acetylated MAP1S, is essential in autophagy regulation. However, we found 
that RASSF1A also had no impact on levels of acetylated MAP1S both in vitro or 
in vivo. Second, although RASSF1A suppression resulted in decreased levels of 
Bcl-2 and p27 in HeLa cells, overexpressing p27 did not restore the decreased 
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autophagy flux caused by RASSF1A suppression. RASSF1A was reported to 
regulate cell cycle and apoptosis and the changes of Bcl-2 and p27 here caused 
by RASSF1A suppression may be involved in cell cycle and apoptosis regulation, 
which needs to be further investigated (30,33-36). Taken together, RASSF1A 
does not regulate autophagy initiation in the same way as its interactive protein 
MAP1S does.  
It is well documented that RASSF1A interacts with Mst1, one of the key 
regulators of the Hippo pathway that regulates organ size and tissue homeostasis 
(130,133). The interaction suggests that RASSF1A may suppress tumorigenesis 
through Hippo pathway. Central to Hippo pathway is a kinase cascade. 
Conventionally, phosphorylated Mst1 kinase leads to the phosphorylation of its 
downstream effector Yap, a transcriptional factor. 14-3-3 protein binds to the 
phosphorylated Yap and retains Yap in the cytoplasm so that Yap cannot 
translocate into nuclear to promote the transcription of its target genes involved in 
cell proliferation, survival, and apoptosis. Studies of in vivo models generally 
support an oncogenic role of Yap and a tumor-suppressive function of Hippo 
pathway (130). Accumulating evidence also shows that dysfunction of Hippo 
pathway occurs in many human cancers (134,135). RASSF1A was reported to 
directly bind with and stabilize Mst1 through preventing its dephosphorylation by 
PP2A (128). Consistent with this report, we found that RASSF1A deletion leads 
to a significant reduction in levels of phosphorylated Mst1 and total Mst1 in mouse 
liver tissues. However, RASSF1A deletion does not alter levels of phosphorylated 
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Yap, total Yap and CTGF. Therefore, at least in mouse liver tissues, RASSF1A 
does not regulate autophagy flux and exert its tumor-suppressive role through 
conventional Hippo pathway. 
It was reported that Mst1 interacts with Beclin1 and enhances its binding 
to Bcl-2/xL to inhibit autophagy flux in cardiomyocytes (136). In this chapter, we 
showed that RASSF1A deletion leads to decreased levels of total and 
phosphorylated Mst1 in mouse liver tissues, which suggests autophagy would be 
activated. However, our results show that autophagy was not activated but 
actually suppressed. In addition, RASSF1A deletion did not alter levels of Bcl-2 
and Beclin1 (data not shown) in mouse liver tissues. Although RASSF1A-
suppressed HeLa cells had a reduced level of Mst1, the interaction between Bcl-
2 and Beclin1 were not altered in RASSF1A-suppressed HeLa cells (data not 
shown). Therefore, at least in mouse liver tissues, RASSF1A does not regulate 
autophagy initiation through Mst1-Beclin1-Bcl-2 pathway.  
It was also reported that Mst1 directly interacts with the hydrophobic 
domain of Akt and the interaction is sufficient to inhibit Akt activity and the 
downstream signaling events (129). We reasoned that RASSF1A may promote 
autophagy initiation through suppressing PI3K-Akt-mTOR pathway, a well-known 
canonical autophagy-suppressive pathway. As expected, RASSF1A depletion 
causes a reduction in Mst1-Akt interaction and thereby activation of PI3K-Akt-
mTOR pathway to inhibit autophagy initiation. Therefore, here we discover an 
alternative mechanism by which Mst1 regulates autophagy initiation through 
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directly binding with and inhibiting Akt activity. Mst1 is a serine-threonine kinase 
but not a dephosphorylase, so here it is impossible for Mst1 itself to directly 
dephosphorylate Akt. Studies showed that Mst1 inhibits Akt activity in a manner 
that depends on its direct binding to Akt, not its phosphotransferase activity (129). 
The hydrophobic domain of Akt that Mst1 binds to is a binding domain for several 
positive and negative regulators of Akt, so it is predicted that Mst1 may be 
competitive with the positive regulators to bind to Akt, or Mst1 may recruit the 
negative regulators to the Mst1-Akt complex to inhibit Akt activity. Understanding 
of the detailed mechanism by which Mst1 inhibits Akt activity needs further 
studies.     
Although RASSF1A promotes autophagy maturation through its interactive 
protein MAP1S, we show here that RASSF1A does not regulate autophagy 
initiation through MAP1S. We previously reported that RASSF1A has a 
mitochondrial location in the absence of intact microtubules (54). Mitochondria as 
well as Golgi complex, endosomes, ER (endoplasmic reticulum) are the potential 
source for the phagophore (also called the isolation membrane) (137). It is widely 
accepted that a phagophore assembly site (PAS) first forms on the membrane of 
above organelles, and then some autophagy machinery docks at, or is delivered 
to the assembly site to be responsible for the formation of the isolation membrane. 
We predict that at the initial stages of autophagy, RASSF1A may locate to the 
phagophore assembly site on mitochondrial membrane and help autophagy 
machinery to assemble phagophore. After autophagy is initiated, cargo-containing 
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autophagosomes need to migrate along microtubules to fuse with lysosomes in 
different subcellular location. At this stage, RASSF1A recruits MAP1S which 
distribute in other subcellular locations onto RASSF1A-stabilized acetylated 
microtubules and bridges LC3-II-associated autophagosomes with microtubules 
through LC3-II interactive MAP1S. Therefore, RASSF1A and MAP1S distribute in 
different subcellular locations and may regulate autophagy initiation by their 
respective mechanisms. After mature autophagosomes form, RASSF1A and 
MAP1S meet with each other on RASSF1A-stabilized acetylated microtubules to 
promote autophagy maturation. 
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CHAPTER VI  
CONCLUSIONS  
 
Hepatocellular carcinomas (HCC) is the second leading cause of cancer 
death worldwide. Its incidence has more than tripled in the United States 
since1980 and the death rates have increased by almost 3% per year since 2000 
(3). The very early stage of HCC is very hard to be diagnosed, while there are no 
very effective treatments for patients with the late stage of HCC (2). Therefore, it 
is very urgent to understand the underlying mechanism of HCC formation for 
developing novel therapeutic strategies. RASSF1A is a tumor suppressor and 
inactivated by promoter hypermethylation in over 90% of HCC patients (42,138). 
Therefore, in this report, we sought out to focus on characterizing the role and 
mechanism of RASSF1A in the development of HCC.    
RASSF1A was suggested to suppress tumorigenesis through multiple 
different mechanisms including cell cycle arrest, apoptosis promotion, 
microtubular stabilization and migration inhibition. Because the interaction of 
RASSF1A with Mst1, RASSF1A was also suggested to suppress tumorigenesis 
through Hippo pathway. However, how RASSF1A causes tumor suppression is 
still debatable. Autophagy activity is inversely correlated with tumor formation 
(16,18,20-22). Autophagy defects enhance oxidative stress and genome 
instability to promote tumorigenesis (23-25). Liver is highly dependent on 
autophagy to maintain its basic functions and autophagy defects promote the 
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malignant transformation of liver cells (58,139). The interaction of RASSF1A with 
autophagy activator MAP1S triggered us to hypothesize that RASSF1A 
suppresses HCC by activating autophagy through MAP1S. We show here first 
time that RASSF1A does not impact the Hippo pathway but acts through Mst1, a 
Hippo pathway-regulatory protein, to promote autophagy initiation through the 
PI3K-Akt-mTOR pathway, a regulatory cascade different from MAP1S-Bcl-2-p27 
noncanonical autophagy pathway; and RASSF1A enhances microtubular 
acetylation and recruits autophagosomes onto acetylated microtubules through 
MAP1S to promote autophagy maturation. RASSF1A deletion leads to autophagy 
defects which induce oxidative stress and DNA damage to accelerate DEN-
induced HCC and shorten mouse survivals. Therefore, we provide here a novel 
mechanism for RASSF1A to activate autophagy and suppress HCC.   
 Overall, we show here first time with solid evidences that RASSF1A is a 
novel autophagy activator; and epigenetically inactivated RASSF1A actually 
promotes HCC by suppressing the initiation and maturation of autophagy process 
(Figure 25). This work not only advances our understanding of the biological 
functions of RASSF1A but also provides a novel paradigm of the prevention and 
therapy of human HCC.  
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While this dissertation has demonstrated that RASSF1A deletion promotes 
HCC by suppressing autophagy, there are still some interesting directions for 
future work to extend the scope of this dissertation. First, we can investigate 
whether overexpression of RASSF1A in mice is able to suppress DEN-induced 
HCC. Specifically, we can generate RASSF1A transgenic mice to examine 
whether RASSF1A overexpression suppresses DEN-induced 
Figure 25. A diagram showing the potential mechanism by which 
RASSFA regulates autophagy and suppresses hepatocarcinogenesis. 
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hepatocarcinogenesis. We can also generate RASSF1A inducible transgenic 
mice and induce RASSF1A expression after mice develop HCC to examine 
whether it can suppress the growth of established HCC. If RASSF1A 
overexpression in mice suppresses HCC, it will further show that RASSF1A is a 
potential target for HCC therapy. RASSF1A is epigenetically inactivated in about 
90% of HCC, so exploring how RASSF1A is regulated and how to reactivate 
RASSF1A expression may provide a novel approach to HCC therapy. Second, 
our study shows that RASSF1A deletion in mice leads to autophagy defects by 
activating PI3K-Akt-mTOR pathway, so we can treat RASSF1A-/- mice with 
mTOR inhibitor, such like rapamycin, to examine whether suppression of mTOR 
prevents HCC development. Third, examining how RASSF1A regulates the 
acetylation of microtubules will help to better understand its basic functions. It is 
known that RASSF1A stabilizes microtubules, but the underlying mechanism is 
unclear. In this study we show that RASSF1A stabilizes microtubules by 
promoting microtubular acetylation; RASSF1A inhibits HDAC6 deacetylase 
activity on microtubules possibly due to its interaction with HDAC6. Future work 
can focus on investigating how the interaction inhibits HDAC6 activity. If 
RASSF1A regulates microtubular acetylation through HDAC6, we can treat mice 
with HDAC6 inhibitor to see whether it can suppress HCC development. We can 
also examine the impact of RASSF1A on α-TAT (α-tubulin acetyl-transferase), 
which may also help to uncover the underlying mechanism. Finally, this study 
mainly focuses on examining the role of RASSF1A in parenchymal hepatocytes 
 101 
 
which perform the majority of hepatic functions. We can extend our studies in 
other non-parenchymal hepatocytes, such like hepatic stellate cells (HSC), 
sinusoidal endothelial cells, phagocytic Kupffer cells and lymphocytes. It is 
reported that autophagy plays an important role in HSC activation, sinusoidal 
endothelial cells-regulated liver ischemia-reperfusion injury, lymphocytes 
development and survival (60, 140). Investigating the role of RASSF1A-regulated 
autophagy in these non-parenchymal hepatocytes may provide novel therapy 
approaches in other liver diseases.    
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